Schizophrenia Research

Ten years: international congress on schizophrenia research
pp. 3-3(1)
Authors: Nusbaum S.; Schulz C.; Tamminga C.

Schizophrenia and hierarchical diagnosis: a clinical study
pp. 5-5(1)
Authors: Bermanzohn P.C.; Porto L.; Siris S.G.

Periodic catatonia: a case report and literature review
pp. 5-5(1)
Authors: Berry S.A.; Rapport D.J.; Kujawa M.J.

Development of a screening interview and brief diagnostic interview for psychotic disorders
pp. 5-5(1)
Authors: Castle D.J.; Jablensky A.V.; Waterreus A.; McGrath J.; Cardy S.; Herrman H.; Gureje O.

Premenstrual dysphoric disorder and it's relation to schizophrenia symptom severity
pp. 5-6(2)
Author: Harris A.H.

The stability of the diagnosis of schizophrenia: a pilot study in a Brazilian university hospital using the opcrit multidiagnostic system
pp. 6-6(1)
Authors: Tortelli A.A.; Nascimento A.F.; Rumi D.O.; Elkis H.

The relationship of schizophrenia and bipolar illness
pp. 6-6(1)
Authors: Lohr J.B.; Caligiuri M.P.

Factors which trigger 'schizophrenia'
pp. 6-7(2)
Authors: Riederer P.; Kornhuber J.

General review on course and prognosis in schizophrenia
pp. 7-7(1)
Authors: Rodado M.J.; Rodado J.; Manzanera F.; Toledo F.; Hernandez J.

Factors associated with the reliability of the best-estimate diagnostic procedure
pp. 7-7(1)
Authors: Roy M.-A.; Maziade M.

The evolution of diagnosis of schizophrenia and affective disorders in Sao Paulo, Brazil
pp. 7-7(1)
Authors: de Toledo M.L.; Elkis H.

Reliability of the structured interview for schizotypy-revised (SIS-R)
pp. 8-8(1)
Author: Vollema M.G.

Personality and family relationships in schizophrenia in the context of the neurodevelopmental hypothesis
pp. 8-8(1)
Authors: Willinger U.; Heiden A.M.; Meszaros K.; Kasper S.; Aschauer H.N.

Proposals for correlative, concurrent studies in the schizophrenias
pp. 8-8(1)
Authors: Young C.W.; Young L.R.

First-episode schizophreniform disorder: comparisons with first-episode schizophrenia
pp. 8-9(2)
Authors: Zarate C.A.; Tohen M.; Hennen J.

An investigation of instruments used to assess negative symptoms in patients with schizophrenia
pp. 11-11(1)
Authors: Bow-Thomas C.C.; Eckert S.L.; Miller A.L.; Diamond P.M.; Velligan D.I.; Funderburg L.G.; True J.E.

Sexuality and schizophrenia: behavioral patterns and clinical correlates
pp. 11-11(1)
Authors: Buckley P.F.; Hyde J.; Winterich D.; Friedman L.; Donenwirth K.

Kinematic analyses of movement velocity can identify motor-related negative phenomena in schizophrenia
pp. 11-11(1)
Authors: Caligiuri M.P.; Lohr J.B.

Conversational repair in childhood onset schizophrenia
pp. 12-12(1)
Authors: Caplan R.; Guthrie D.; Komo S.

Are psychopathologic domains independent diseases?
pp. 12-12(1)
Author: Carpenter W.T.

Development of the psychosis observation rating scales
pp. 12-12(1)
Authors: Catts S.V.; Andrews S.; Bird K.; Ward P.B.; Liebert B.J.; Spinks N.; McConaghy N.

Correlates and course of negative symptoms in schizophrenic patients
pp. 12-13(2)
Authors: Cohen R.; Watzl H.; Hubmann W.; Mohr F.; Schlenker R.; Werther P.

Quality of life in outpatients with schizophrenia
pp. 13-13(1)
Authors: Dickerson F.; Boronow J.; Ringel N.; Parente F.

Expressed emotion and definition of self in parents of long-term stable schizophrenia outpatients
pp. 13-13(1)
Authors: Docherty N.M.; Cutting L.P.; Bers S.A.

A transcultural comparison of schizophrenia in nineteenth century Scotland and North America
pp. 13-14(2)
Author: Doody G.A.

Enduring negative or deficit symptoms in first-episode psychosis: comparison of 3 methods using follow-up data
pp. 14-14(1)
Authors: Edwards J.; McGorry P.D.; Waddell F.; Harrigan S.

Aggression among patients with treatment refractory psychoses
pp. 14-14(1)
Authors: Ehmann T.S.; Ross D.; Au T.; Smith G.N.; Flynn S.W.; Altman S.; Honer W.G.

Cigarette smoking: the first episode experience
pp. 14-14(1)
Authors: Elkins K.; Curry C.M.; Harrigan S.M.; McGorry P.D.

Delusions and autism in schizophrenia and immunological alterations
pp. 14-15(2)
Authors: Fabisch H.; Fabisch K.; Langs G.; Wieselmann G.; Tilz G.P.; Zapotoczky H.G.

Obsessive-compulsive symptoms in schizophrenia
pp. 15-15(1)
Authors: Fabisch K.; Fabisch H.; Langs G.; Wieselmann G.; Zapotoczky H.G.

Suicide risk factors in schizophrenia
pp. 15-15(1)
Authors: Fenton W.S.; McGlashan T.H.; Blyler C.R.

PANSS symptom factors in schizophrenia
pp. 15-15(1)
Authors: Fredrikson D.H.; Steiger J.M.; MacEwan G.W.; Altman S.; Kopala L.C.; Flynn S.W.; Liddle P.F.; Honer W.G.

Cluster analysis: a useful tool for identifying homogeneous subtypes of schizophrenia?
pp. 16-16(1)
Authors: Goldman M.; Tandon R.; Decker L.

The association between positive symptomatology and aggressive behavior in schizophrenia outpatients
pp. 16-16(1)
Authors: Gordinier S.; Hall M.; Docherty N.

Pubertal timing and syndromes of schizotypy: a replication
pp. 16-16(1)
Authors: Gruzelier J.; Kaiser J.

Suicidal behavior in schizophrenia: an examination of attempters and nonattempters
pp. 16-17(2)
Authors: Harkavy-Friedman J.M.; Restifo K.; Malaspina D.; Kaufmann C.A.; Amador X.; Yale S.; Gorman J.M.

Longitudinal course and outcome: schizophrenia versus other psychotic disorders
pp. 17-17(1)
Authors: Harrow M.; Sands J.R.

The putative phenomenological correlates of sensory gating: factor analyses and a self-report rating scale
pp. 17-17(1)
Authors: Hetrick W.P.; Smith D.A.; Spruiell E.; Sandman C.A.; Bunney W.E.

Patterns of symptom change: a longitudinal analysis
pp. 17-18(2)
Authors: Hull J.W.; Smith T.E.; Anthony D.T.; Goodman M.S.; Kentros M.K.; Sepe O.; Yanulis M.A.; Li C.

Symptom dimensions in schizophrenia: a comparison of white and African-Caribbean patients
pp. 18-18(1)
Authors: Hutchinson G.; Takei N.; Fahy T.A.; Gilvarry C.; Murray R.M.

Symptom and disease specificity of brain behavior functions in bipolar disorder and schizophrenia
pp. 18-18(1)
Authors: Kohler C.; Gur R.C.; Mozley L.H.; Gur R.E.

Sex differences in self-reported schizotypal symptoms in relatives of schizophrenic probands
pp. 18-19(2)
Authors: Kremen W.S.; Faraone S.V.; Seidman L.J.; Toomey R.; Lyons M.J.; Goldstein J.M.; Tsuang M.T.

Recruitment of schizophrenia spectrum personality subjects from the community
pp. 19-19(1)
Authors: Kunkel R.; Adami H.; Ross D.; Thaker G.K.

Social problem solving and social withdrawal in adolescents at-risk for schizophrenia
pp. 19-19(1)
Authors: Logan M.C.; Schiffman J.; Walder D.; Walker E.F.

Psychopathology in first-episode familial schizophrenia
pp. 19-19(1)
Authors: Nilsson A.; Ahrens B.

Morphometry in schizophrenia revisited: height and its relationship to premorbid function
pp. 19-20(2)
Authors: Nopoulos P.; Andreasen N.

A profile of obsessive compulsive symptoms in schizophrenia
pp. 20-20(1)
Authors: Porto L.; Bermanzohn P.; Siris S.; Pollack S.; Morrissey R.

Core negative and positive symptoms in schizophrenia
pp. 20-20(1)
Authors: Quinlan D.M.; McGlashan T.H.; Schuldberg D.; Glazer W.

Emotional response and symptoms of schizophrenia
pp. 20-21(2)
Authors: Quirk S.W.; Strauss M.E.; Sloan D.M.

Predictors of assaultive long-stay schizophrenic patients: national study
pp. 21-21(1)
Authors: Rabinowitz J.; Mark M.; Popper M.

Prediction of outcome following a first episode of schizophrenia. A preliminary study
pp. 21-21(1)
Authors: Rodado M.J.; Manzanera F.; Lopez J.C.; Sanchez de las Matas M.; Aguilar E.; Hernandez J.

Agreement between SPQ and MMPI-2 as measures of schizotypy
pp. 21-21(1)
Authors: Sarkin A.J.; Dionisio D.P.; Hillix W.A.; Granholm E.L.

Schizophrenia and substance abuse: characteristics associated with the high rate of comorbidity
pp. 22-22(1)
Authors: Scheller-Gilkey G.; Thomas S.; Chadwick N.; Woolwine B.; Miller A.

Negative symptom severity and general cognitive impairment increase with duration of initially untreated psychosis
pp. 22-22(1)
Authors: Scully P.J.; Coakley G.; Kinsella A.; Waddington J.L.

Laterality in parkinson's disease and susceptibility to psychosis
pp. 22-22(1)
Authors: Shergill S.S.; Walker Z.; Katona C.L.E.

Stability of neurological soft signs in chronic schizophrenics: relationship to psychopathology, smoking, and atypical neuroleptics
pp. 23-23(1)
Authors: Smith R.C.; Hussain M.I.; Chowdhury S.A.; Jafri S.M.

Computerized self-assessment of psychosis severity [COSAPS] in schizophrenia. A preliminary report on the COSAPS-questionnaire
pp. 23-23(1)
Authors: Stern R.G.; Fudge R.; Sisson C.; Alan E.; Crichton J.; Schmeidler J.; Losonczy M.

Rater gender and symptom ratings of patients with schizophrenia
pp. 23-23(1)
Authors: Swanson C.L.; Turetsky B.I.; Bilker W.; Gur R.C.; Gur R.E.

Negative, positive, and disorganized symptom dimensions in schizophrenia, major depression, and bipolar disorder
pp. 24-24(1)
Authors: Toomey R.; Faraone S.V.; Simpson J.C.; Tsuang M.T.

Sequential models of schizophrenia courses
pp. 24-24(1)
Authors: Tschacher W.; Scheier C.

Olfactory discrimination and acuity in relation to positive and negative symptoms
pp. 24-24(1)
Authors: Vernon L.; Bartel B.; Brown K.; Steele V.; Cho J.; Simon M.; Jaskiw G.E.; Strauss M.E.

Three dimensions of selfreport schizotypy
pp. 24-25(2)
Authors: Vollema M.G.; Hoijtink H.

The ACL as a quick screen in the determination of readiness for supported or competitive employment for patients with schizophrenia: a correlation of productivity and ACL scores
pp. 25-25(1)
Authors: Walisch C.J.; Tapp A.

Symptoms cluster analysis on and off neuroleptic medication
pp. 25-25(1)
Authors: Warfel D.T.; Lahti A.C.; Corey T.; Weiler M.A.; Medoff D.; Tamminga C.A.

The prevalence and predictive validity of early depressive symptoms in the course of schizophrenia
pp. 25-25(1)
Authors: Wassink T.H.; Rose S.; Flaum M.; Andreasen N.C.

Symptom severity in chronic schizophrenia: effect of age and cognitive impairment
pp. 25-26(2)
Authors: White L.; Parrella M.; Harvey P.D.; Powchick P.; Davidson M.; Opler L.; Lindenmayer J.

Clinical variables associated with suicide in patients with schizophrenia spectrum disorders
pp. 26-26(1)
Authors: Ziebell S.; Schultz S.; Andreasen N.

Hyperlocomotion elicited by ventral hippocampal stimulation in rats: influence of dopamine
pp. 27-27(1)
Authors: Bardgett M.E.; Brenner D.M.

Adhesive and positional specification in the developing forebrain
pp. 27-27(1)
Authors: Gotz M.; Cremisi F.; Price J.

A neural model of psychosis in temporal lobe epilepsy
pp. 27-28(2)
Authors: Diforio D.; Walker E.F.

The effect of chronic haloperidol treatment on dendritic spines in the rat striatum
pp. 28-28(1)
Authors: Kelley J.J.; Gao X.M.; Tamminga C.A.; Roberts R.C.

An animal model of relevance to the deficit syndrome
pp. 28-28(1)
Author: Kirkpatrick B.

Limbic-cortical neuropathology in rats: a developmental study
pp. 28-28(1)
Authors: Montgomery E.-M.E.; Bardgett M.E.; Csernansky J.G.

Postpubertal manifestations of dopaminergic hyperactivity following neonatal lesions of the mediodorsal thalamic nuclei
pp. 29-29(1)
Authors: Rajakumar N.; Williamson P.C.

Schizophrenia-like limbic-cortical neuropathology in rats: fos response to antipsychotics
pp. 29-29(1)
Authors: Roe D.L.; Bardgett M.E.; Csernansky C.A.; Csernansky J.G.

Localization of D₄-like dopamine receptors on corticostriatal projections and intrinsic striatal neurons
pp. 29-30(2)
Authors: Tarazi F.I.; Yeghiayan S.K.; Campbell A.; Baldessarini R.J.

MK-801 induced expression of FOS, FOS-related antigens and heat shock protein-70 in the rat retrosplenial granular cortex
pp. 30-30(1)
Authors: Xia Z.; Fan X.-D.; Yu P.H.; Boulton A.A.

Regional measurement of pH in postmortem brain tissue
pp. 31-31(1)
Authors: Bigelow L.B.; Cervenak J.; Herman M.M.; Kleinman J.E.; Torrey E.F.

Correlation of schizophrenia and bipolar disorder with cytokine and nitric oxide synthase levels from post-mortem brain tissues
pp. 31-31(1)
Authors: Bobo L.; Novak N.; Johnston N.; Leister F.; Torrey E.F.; Yolken R.

Biochemical heterogeneity in schizophrenia due to gender: a multivariate study of post-mortem brain biochemistry
pp. 31-32(2)
Authors: Carlsson A.; Waters N.; Waters S.H.; Carlsson M.; Gottfries C.-G.; Martin P.; Hansson L.O.

Muscarinic M₁ receptors in the caudate putamen of patients with schizophrenia: decreased receptor density is not accompanied by decreased receptor mRNA
pp. 32-32(1)
Authors: Copolov D.; Crook J.; Opeskin K.; Hill C.; Keks N.; Dean B.

Lateralised alterations in hippocampal MAP2 in schizophrenia
pp. 32-32(1)
Authors: Cotter D.R.; Doshi B.; Kerwin R.W.; Everall I.P.

A possible muscarinic involvement in schizophrenia: reduced M₁ receptor measurement in human hippocampus
pp. 32-33(2)
Authors: Crook J.M.; Tomaskovic E.M.; Dean B.; Copolov D.

Second messengers in schizophrenia: changes in protein kinase C and adenylate cyclase
pp. 33-33(1)
Authors: Dean B.; Opeskin K.; Pavey G.; Hill C.; Keks N.

Absence of neuropathological and neurochemical sequela of cognitive deficits in elderly schizophrenics
pp. 33-33(1)
Authors: Haroutunian V.; Powchik P.; Gabriel S.; Purohit D.P.; Perl D.P.; Davis K.L.

Cortex and serotonin in schizophrenia: effects of antipsychotic treatment?
pp. 33-34(2)
Authors: Joyce J.N.; Gurevich E.V.

Reduced levels of synaptic proteins in the prefrontal cortex in schizophrenia
pp. 34-34(1)
Authors: Karson C.N.; Griffin W.S.; Mrak R.E.; Sturner W.Q.; Shillcutt S.; Guggenheim F.G.

Diagnostic instrument for brain studies (DIBS)
pp. 34-34(1)
Authors: Keks N.A.; Hill C.; Roberts S.; Dean B.; Opeskin K.; MacKinnon A.; Copolov D.

[³H]-neurotensin receptor levels in human postmortem brain. Comparison of normals to schizophrenics off-, or on-antipsychotic drugs at death
pp. 34-34(1)
Authors: Lahti R.A.; Roberts R.C.; Cochrane E.V.; Tamminga C.A.

[³H]-NGD-94-1 binding in human postmortem brain of normals and schizophrenics off-, or on-antipsychotic drugs at death
pp. 35-35(1)
Authors: Lahti R.A.; Roberts R.C.; Cochrane E.V.; Primus R.J.; Gallager D.W.; Tamminga C.A.

Postmortem glutamate receptor binding in the prefrontal cortex of schizophrenics and controls
pp. 35-35(1)
Authors: Noga J.T.; Hyde T.M.; Bachus S.E.; Herman M.M.; Weinberger D.R.; Kleinman J.E.

Parvalbumin-IR neurons in the frontal cortex in schizophrenia
pp. 35-36(2)
Authors: Reynolds G.P.; Beasley C.L.

Post-mortem determination of kynurenine and kynurenic acid levels in the brains of schizophrenic patients
pp. 36-36(1)
Authors: Schwarcz R.; Wu H.-Q.; Rassoulpour A.; Tamminga C.A.; Medoff D.R.; Roberts R.C.

Phosphoinositide signaling activity in postmortem brain from subjects with schizophrenia or alcohol dependence
pp. 36-36(1)
Authors: Stockmeier C.A.; Song L.; Dilley G.E.; Meltzer H.Y.; Overholser J.C.; Jope R.S.

The distribution of glutamate decarboxylase₆₅-immunoreactive (GAD₆₅-IR) terminals on pyramidal (PN) and nonpyramidal (NP) neurons in cingulate cortex of schizophrenics (SZs)
pp. 37-37(1)
Authors: Benes F.M.; Todtenkopf M.S.

Brain dysgenesis in late onset schizophrenia (paraphrenia): comparison with controls and patients with schizophrenia
pp. 37-37(1)
Authors: Coura S.H.; Elkis H.

An immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia: absence of significant gliosis
pp. 37-37(1)
Authors: Damadzic R.; Goldenson D.A.; Saunders R.C.; Krimer L.S.; Bigelow L.B.; Herman M.M.; Kleinman J.E.

The frontal lobe in schizophrenics and control subjects: a volumetric post-mortem-study
pp. 37-38(2)
Authors: Falkai P.; Bogerts B.; Schneider T.; Pfeiffer U.; Honer W.G.; Kawasaki Y.

Serotonergic neurons in the dorsal raphe nuclei in schizophrenia
pp. 38-38(1)
Authors: Garey L.J.; Kavia R.B.C.; von Bussmann K.A.; Gentleman S.M.

A quantitative study of parvalbumin-immunoreactive interneurons in the cingulate gyrus of schizophrenic patients
pp. 38-38(1)
Authors: Leclercq P.D.; McKenzie J.E.; Royston M.C.; Gentleman S.M.; Mortimer A.M.; von Bussmann K.A.; Hornstein C.; Bauer M.; Hirsch S.R.; Garey L.J.

Schizophrenia and subclasses of local circuit neurons in the prefrontal cortex
pp. 38-39(2)
Authors: Lewis D.A.; Woo T.-U.; Miller J.L.; Soloway A.S.

Vulnerable prefrontal cortical circuits in schizophrenia
pp. 39-39(1)
Author: Lewis D.A.

Specificity of decreased spine density on layer III pyramidal cells in schizophrenia
pp. 39-39(1)
Authors: Lewis D.A.; Glantz L.A.

The ultrastructural pathology of myelinated fibers and oligodendroglial cells in autopsied caudate nucleus of schizophrenics
pp. 39-40(2)
Authors: Orlovskaya D.D.; Denisov D.V.; Uranova N.A.

An assessment of purkinje cell placement in the superior cerebellar vermis in mental disease
pp. 40-40(1)
Authors: Paltan-Ortiz J.D.; Helmkamp C.E.; Bigelow L.B.; Torrey E.F.; Kleinman J.E.; Herman M.M.

Pyramidal neurons immunoreactive for nonphosphorylated neurofilament protein in schizophrenia: a postmortem study of the prefrontal cortex
pp. 40-40(1)
Authors: Pierri J.N.; Lewis D.A.

A neuroanatomical study of glial cells in schizophrenia
pp. 40-41(2)
Authors: Radewicz K.; Garey L.J.; Hirsch S.R.; Mortimer A.M.; Hornstein C.; Bauer M.; Reynolds R.

Marked glial neuropathology in prefrontal cortex distinguishes bipolar disorder from schizophrenia
pp. 41-41(1)
Authors: Rajkowska G.; Selemon L.D.; Goldman-Rakic P.S.

The immunocytochemical localization of tyrosine hydroxylase in the human substantia nigra: an ultrastructural study
pp. 41-41(1)
Authors: Roberts R.C.; McKim R.; Kung L.; Crosby K.; Chute D.J.

Morphometric study of synaptic size in autopsied prefrontal cortex, caudate nucleus and substantia nigra of schizophrenics
pp. 41-42(2)
Authors: Uranova N.A.; Orlovskaya D.D.; Kolomeets N.S.; Vikchreva O.V.; Zimina I.S.; Denisov D.V.

Thy-1 distribution in human frontal cortex from controls and patients with schizophrenia or bipolar disorder
pp. 42-42(1)
Authors: Webster M.J.; Vawter M.; Freed W.J.

Hippocampal presynaptic proteins in schizophrenia
pp. 42-42(1)
Authors: Young C.; Beach T.G.; Arima K.; Falkai P.; Honer W.G.

Characterizing heritable psychopathology among the biological relatives of individuals with schizophrenia
pp. 43-43(1)
Author: Ingraham L.J.

Schizophrenics and their adopted-away offspring the finnish adoptive family study of schizophrenia
pp. 43-43(1)
Authors: Tienari J.P.; Wynne C.L.; Laksy K.; Kurki-Suonio K.; Sorri A.; Lahti I.; Moring O.J.; Wahlberg K.-E.H.

The genetic epidemiology of schizophrenia in a finnish twin cohort
pp. 43-44(2)
Authors: Cannon T.D.; Kaprio J.; Lonnqvist J.; Huttunen M.; Koskenvuo M.

Assortative mating and lifetime DSM-III-R outcome in offspring of schizophrenic and normal parents
pp. 44-44(1)
Authors: Finkelstein R.J.J.; Cannon D.T.; Mednick A.S.; Parnas J.; Schulsinger F.

Evaluation of the effectiveness of early predictors of schizophrenia spectrum disorders in the New York high-risk project
pp. 44-44(1)
Authors: Erlenmeyer-Kimling L.; Rock D.; Janal M.; Amminger G.P.; Squires-Wheeler E.; Ott S.; Rende R.; Cornblatt B.; Roberts S.; Pape S.

The New York high-risk project: social and general intelligence in subjects at risk for and prior to onset of schizophrenia
pp. 44-44(1)
Authors: Ott S.L.; Spinelli S.; Rock D.; Roberts S.; Amminger P.G.; Erlenmeyer-Kimling L.

Cognitive/neuropsychological abnormalities in the parents of children with a schizophrenic disorder
pp. 45-45(1)
Authors: Asarnow R.F.; Nuechterlein K.H.; Torquato R.; Subotnik K.; Fogelson D.

Object alteration deficits in first-degree relatives of schizophrenic patients
pp. 45-45(1)
Authors: Faraone S.V.; Seidman L.J.; Oscar-Berman M.; Kremen W.S.; Toomey R.; Tsuang M.T.

What clinical characteristics distinguish relatives of schizophrenics from normal controls?
pp. 45-45(1)
Authors: Levy D.L.; Bloom R.; Matthysse S.; Teraspulsky L.; Mendell N.R.; Holzman P.S.

MMPI profiles of first-degree relatives of recent-onset schizophrenia probands
pp. 46-46(1)
Authors: Nuechterlein K.H.; Subotnik K.L.; Asarnow R.F.; Gottesman I.I.; Fogelson D.L.; Payne D.L.; Torquato R.D.

Increase of neurological abnormalities in females with schizotypal personality disorder from families multiply affected with schizophrenia
pp. 46-46(1)
Authors: Sigmundsson T.; Takei N.; Griffiths T.D.; Birkett P.B.; Sharma T.; Frangou S.; Murray R.M.

MMPI differences among first-degree relatives of probands with childhood-onset schizophrenia, attention deficit disorder, and normal control children
pp. 46-46(1)
Authors: Subotnik K.L.; Asarnow R.F.; Nuechterlein K.H.; Payne D.L.; Fogelson D.L.; Gottesman I.I.

Reduced preexposure effect and impaired associative learning in schizophrenia-affected families: a study of latent inhibition and the kamin blocking effect
pp. 47-47(1)
Authors: Serra A.M.; Toone B.; Jones S.; Gray J.A.

The factor structure of schizophrenia spectrum signs and symptoms in first-degree relatives of schizophrenic patients from the UCLA family members study
pp. 47-47(1)
Authors: Fogelson D.L.; Nuechterlein K.H.; Asarnow R.F.; Payne D.L.; Subotnik K.L.; Giannini C.

Morbid risk of affective psychoses in the relatives of white and African-Caribbean schizophrenic probands
pp. 47-47(1)
Authors: Hutchinson G.; Takei N.; Fahy T.A.; Gilvarry C.; Murray R.M.

Affective illness in the mother as a risk factor for obstetric complications
pp. 47-48(2)
Authors: Marcelis M.; van Os J.; Sham P.; Jones P.; Gilvarry K.; Murray R.

Psychopathological dimensions and familial morbid risk of psychosis
pp. 48-48(1)
Authors: Marcelis M.; van Os J.; Sham P.; Jones P.; Gilvarry K.; Murray R.

How do co-familial traits segregate?
pp. 48-48(1)
Authors: Matthysse S.; Levy D.L.; Deutsch C.; Bloom R.; Coleman M.J.; Yurgelun-Todd D.; Holzman P.S.

Spatial working memory impairment in schizophrenics and their relatives
pp. 48-49(2)
Authors: Snitz B.E.; Feil K.J.; Zald D.H.; Iacono W.G.

Verbal memory deficits in schizophrenic patients and their siblings
pp. 49-49(1)
Authors: White P.T.; Cannon T.D.; Gur R.C.

Abnormal subjective experiences and neuropsychological deficits in first-degree relatives of schizophrenics
pp. 49-49(1)
Authors: Wieneke A.; Schultze-Lutter F.; Steinmeyer E.M.; Klosterkotter J.

Lateral ventricular enlargement in schizophrenic probands and their siblings with schizophrenia-related disorders
pp. 49-50(2)
Authors: Silverman J.M.; Li G.; Smith C.J.; Song L.G.; Mohs R.C.; Siever L.J.; Davis K.L.

Sibling concordance for schizophrenia spectrum traits
pp. 50-50(1)
Authors: Squires-Wheeler E.; Skodol A.; Erlenmeyer-Kimling L.

A susceptibility locus for schizophrenia on chromosome 6 using positive symptom scores as quantitative traits
pp. 50-50(1)
Authors: Bassett A.S.; Honer W.G.; Chow E.; McAlduff J.; Hodgkinson K.A.; Kirkham S.J.; Brzustowicz L.M.

Evidence for a resistance locus for schizophrenia close to the HLA DQB1 and DRB1 gene loci on chromosome 6p21.3
pp. 50-51(2)
Authors: Wright P.; Donaldson P.T.; Underhill J.A.; Choudhuri K.; Doherty D.G.; Murray R.M.

Evidence from a transmission/disequilibrium study that alleles of the DRB1^*04 gene on chromosome 6p21.3 may protect against schizophrenia
pp. 51-51(1)
Authors: Wright P.; Dawson E.; Donaldson P.T.; Underhill J.A.; Sham P.C.; Gill M.; Nanko S.; Owen M.J.; McGuffin P.; Murray R.M.

Association between schizophrenia and markers on chromosome 6p21
pp. 51-51(1)
Authors: Nimgaonkar V.L.; Rudert W.A.; Zhang F.; Gentry K.; Barron Y.; Snider A.; Zhang X.R.; Ganguli R.; Trucco M.

Major psychoses and a potential vulnerability locus on 6p24-p22 in the eastern Quebec population
pp. 52-52(1)
Authors: le groupe IREP and Chantal Merette; Maziade M.; Roy M.-A.; Bissonnette L.; Martinez M.; Cliche D.; Fournier J.-P.; Montgrain N.

Linkage of a chromosome 15 locus to a neurophysiological deficit in schizophrenia
pp. 52-52(1)
Authors: Leonard S.; Byerley W.; Myles-Worsley M.; Olincy A.; Waldo M.; Adler L.; Coon H.; Freedman R.

Linkage studies in schizophrenia and affective disorders in European populations
pp. 52-52(1)
Authors: Maier W.; Albus M.; Lerer B.; Schwab S.; Noethen N.; Risch N.; Fimmers R.; Propping P.; Wildenauer D.B.

A linkage disequilibrium study of chromosome 4p16 and schizophrenia
pp. 53-53(1)
Authors: Shaikh S.; Collier D.; Chioza B.; Tao L.; Xiche L.; Kerwin R.

Velo-Cardio-Facial Syndrome: a true genetic subtype of schizophrenia?
pp. 53-53(1)
Authors: Hodgkinson K.A.; Chow E.; Correia S.; Scutt L.; McAlduff J.; Beatty B.; Squire J.; Weksberg R.; Bassett A.S.

Velocardiofacial syndrome (VCFS) in schizophrenia: cognitive features
pp. 53-53(1)
Authors: Bury A.S.; Chow E.W.C.; Weksberg R.; Correia S.; Scutt L.; Bassett A.S.

Craniofacial dysmorphology in schizophrenia
pp. 53-54(2)
Authors: Deutsch C.K.; Price S.F.; Wussler J.; D'Agostino R.

Upward shift in the distribution of dysmorphic features in schizophrenia
pp. 54-54(1)
Authors: Lane A.; Larkin C.; Waddington J.L.; O'Callaghan E.

Anticipation and imprinting in schizophrenia: results from a large representative Canadian archival sample
pp. 54-54(1)
Authors: Bassett A.S.; Scutt L.; Correia S.; Bomba M.; Husted J.M.

Anticipation and cohort-effect in schizophrenia
pp. 54-55(2)
Authors: Heiden A.; Mag U.W.; Scharfetter J.; Meszaros K.; Kasper S.; Aschauer H.N.

Large or expanded CAG/CTG trinucleotide repeats as an etiological factor in schizophrenia
pp. 55-55(1)
Authors: Vincent J.B.; Meltzer H.Y.; Lieberman J.A.; Breschel T.; McGinnis M.; Macedo A.; Azevedo M.H.; Pato C.N.; Torrey E.F.; Gottesman I.I.; Petronis A.; Kennedy J.L.

Detection, quantitation and analysis of genomic differences in monozygotic twins
pp. 55-55(1)
Authors: Smith C.L.; Broude N.E.; Lukyanov S.A.; Graber J.H.; Sverdlov E.D.

Analysis of genomic DNA from monozygotic twins discordant for schizophrenia
pp. 55-56(2)
Authors: Yeping S.; Lin J.-J.; Shuojia L.; Leister F.; Yolken R.

Molecular genetic analysis of a translocation breakpoint associated with schizophrenia
pp. 56-56(1)
Authors: Devon R.S.; Millar J.K.; Anderson S.; Christie S.; Maule J.C.; Shibasaki Y.; Evans K.L.; Brown J.; Wilson-Annan J.C.; Lawson D.; Gosden J.R.; Muir W.J.; Blackwood D.H.R.; St. Clair D.M.; Brookes A.J.; Porteous D.J.

Mental correlates of neuromotoric deviation in 6-year-olds at heightened risk for schizophrenia
pp. 56-56(1)
Authors: McNeil T.F.; Cantor-Graae E.; Blennow G.

Mapping genes for schizophrenia with discordant sib-pair sampling
pp. 56-57(2)
Author: Moldin S.O.

The NIMH schizophrenia genetics initiative: a new scientific resource
pp. 57-57(1)
Authors: Moldin S.O.; Wynne D.; Shore D.

Genetics, haloperidol-induced catalepsy and haloperidol effects on prepulse inhibition of acoustic startle
pp. 59-59(1)
Authors: Hitzemann R.; McCaughran J.; Kline L.; Fochtman L.; Mahjubi I.

Characterization of inbred mouse strain differences in startle and the prepulse inhibition model of schizophrenia
pp. 59-59(1)
Authors: Paylor R.; Pickar D.; Crawley J.N.

Regulation of glutamate receptor gene expression in the rat brain following antipsychotic drug treatment
pp. 59-60(2)
Authors: Riva M.A.; Tascedda F.; Lovati E.; Racagni G.

Inheritance of a schizophrenia-like deficit in auditory gating fits a one gene model in inbred mouse strains
pp. 60-60(1)
Authors: Stevens K.E.; Collins A.C.; Marks M.J.; Stitzel J.A.; Freedman R.

Molecular approaches towards the evaluation of the retroviral hypothesis for schizophrenia
pp. 60-60(1)
Authors: Deb P.; Klempan T.A.; Singh S.M.; O'Reilly R.L.

Viral and virus-related RNA transcripts are differentially expressed in the brains of individuals with schizophrenia and bipolar disorder
pp. 60-61(2)
Authors: The Stanley Neuropathology Consortium; Yee F.; Johnston N.L.; Leister F.; Li S.; Ross C.A.; Torrey E.F.; Yolken R.H.

Molecular analyses of brains from individuals with schizophrenia-evidence of viral infections
pp. 61-61(1)
Authors: the Stanley Neuropathology Consortium; Yolken R.H.; Yee F.; Johnston N.; Leister F.; Bobo L.; Jafari N.; Brando L.J.; De I.; Torrey E.F.

The effects of treated and untreated nicotine withdrawal on smokers with schizophrenia
pp. 63-63(1)
Authors: Dalack G.W.; Becks L.; Hill E.; Pomerleau O.; Meador-Woodruff J.H.

Cortisol response to a psychosocial stressor in schizophrenia
pp. 63-63(1)
Authors: Gispen-de Wied C.C.; Jansen L.M.C.; van der Linden J.A.; Kahn R.S.

Enhanced cortisol response to cold stress in hyponatremic schizophrenics
pp. 63-63(1)
Author: Goldman M.B.

Presynaptic dopaminergic markers in human striatum during development and aging
pp. 63-64(2)
Author: Haycock J.W.

Arachidonic and docosahexaenoic acid levels in blood in schizophrenics who do and do not flush to oral niacin
pp. 64-64(1)
Authors: Horrobin D.F.; Vaddadi K.S.; Glen A.I.M.; Cooper S.; Fahey J.; Rybakowski J.; Shay J.

Neurotrophin-3 levels in human cerebrospinal fluid (CSF), a cross-sectional study of general hospital patients and a group with schizophrenia
pp. 64-64(1)
Authors: Jarskog L.F.; Lindgren J.C.; Hong X.; McEvoy J.P.; Gilmore J.H.

Repeated measures in schizophrenia research: modelling drug withdrawal effects on plasma HVA and MHPG
pp. 64-65(2)
Authors: Kelley M.E.; van Kammen D.P.; Yao J.K.

Anticardiolipin antibodies in schizophrenia
pp. 65-65(1)
Authors: Kolyaskina G.I.; Burbaeva O.A.; Sekirina T.P.

Increased cyclooxygenase/lipooxygenase activity in platelets from schizophrenic subjects indicates impaired arachidonic acid metabolism
pp. 65-65(1)
Authors: Khan N.S.; Das I.; Puri B.K.; Hirsch S.R.

Gonadotropin activity in men and women with schizophrenia
pp. 65-66(2)
Authors: Kulkami J.; de Castella A.; Taffe J.

Menstrual cycle changes in schizophrenia
pp. 66-66(1)
Authors: Kulkami J.; de Castella A.; Thompson K.; Smith D.

Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers
pp. 66-66(1)
Authors: Olincy A.; Young D.A.; Freedman R.

Plasma TBARS levels in unmedicated chronic schizophrenic patients
pp. 66-66(1)
Authors: Peet M.; Zhi J.Z.; Selvam K.; Ramchand C.N.

Biochemical alterations associated with membrane pathology in schizophrenia. A study using fibroblasts from schizophrenics
pp. 66-67(2)
Authors: Ramchand C.N.; Das I.; Ramchand R.; Lee K.H.; Peet M.

Free radical pathology in schizophrenia: a review
pp. 67-67(1)
Authors: Reddy R.; Yao J.K.

CSF HVA/5HIAA ratio is normally distributed in unmedicated and clozapine treated schizophrenics as compared with normal controls
pp. 67-67(1)
Authors: Risch S.C.; Molloy M.; Batchelor M.; Speer A.; Lewine R.R.J.; DeVane C.L.; George M.

Aminochromes, neuromelanin and schizophrenia
pp. 67-68(2)
Author: Smythies J.

Changes of plasma homovanillic acid in neuroleptic responsive and non-responsive schizophrenics
pp. 68-68(1)
Authors: Hae S.S.; Chul E.K.

Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia
pp. 68-68(1)
Authors: Guochuan T.; van Kammen D.P.; Shao C.; Kelley M.E.; Coyle J.T.

CSF neuronal cell adhesion molecule (N-CAM) in schizophrenia
pp. 68-69(2)
Authors: van Kammen D.P.; Poltorak M.; Kelley M.E.; Yao J.K.; Gurklis J.A.; Peters J.L.; Hemperly J.J.; Freed W.J.

The role of immune measures in psychosis and stress sensitivity in schizophrenia
pp. 69-69(1)
Authors: van Kammen D.P.; McAllister C.G.; Kelley M.E.; Mathe A.A.; Brown W.A.; Yao J.K.; Gurklis J.A.

Cellular effects of serum osmolarity changes in polydipsia-hyponatremia
pp. 69-69(1)
Authors: Verghese C.; Levitan I.; Garber S.; Nair C.; Abraham G.; Josiassen R.

Stress and schizophrenia: new neurochemical findings and models
pp. 69-70(2)
Authors: Walker E.F.; Diforio D.; Logan C.

Skin flushing in response to graded doses of topical niacin: a new test which distinguishes schizophrenics from controls
pp. 70-70(1)
Authors: Ward P.; Sutherland J.; Glen E.; Glen A.I.M.; Horrobin D.F.

Obstetrical complications and stress-responsitivity in adolescents at-risk for schizophrenia
pp. 70-70(1)
Authors: Weinstein D.D.; Lowey R.; Diforio D.; Walker E.F.

Neuroleptic effects on antioxidant defense system enzymes in schizophrenia
pp. 70-71(2)
Authors: Yao J.K.; van Kammen D.P.; Reddy R.D.

Striatal acetylcholine release correlates with behavioral sensitization in rats withdrawn from chronic amphetamine
pp. 73-73(1)
Authors: Abercrombie E.D.; Bickerdike M.J.

Serotonergic modulation of the GABA system in the rat prefrontal cortex
pp. 73-73(1)
Authors: Abi-Saab W.M.; Deutch A.Y.

Striatal dopamine D₂, cortical 5HT_2A and striatal neurotensin receptor levels in neonatal hippocampal lesioned (NHL) male and female rats
pp. 73-74(2)
Authors: Black M.; Hitchcock J.; van Giersbergen P.; Sorensen S.

Involvement of glutamatergic mechanisms in the biochemical actions of the atypical neuroleptic clozapine
pp. 74-74(1)
Authors: Bubser M.; Young C.D.; Deutch A.Y.

Olanzapine increases extracellular dopamine release and blocks dopamine, serotonin and muscarinic receptors in vivo
pp. 74-74(1)
Authors: Bymaster F.P.; Li X.-M.; Carter P.A.; Wong D.T.; Perry K.W.

Clozapine impairs temporal perception and stimulus control in rats
pp. 75-75(1)
Authors: Compton A.D.; Drew M.R.; Golden K.M.; Wiley J.L.

The antiseizure efficacies of MK-801, phencyclidine, ketamine and memantine are altered selectively by stress
pp. 75-75(1)
Authors: Deutsch S.I.; Mastropaolo J.; Riggs R.L.; Rosse R.B.

Behavioral and biochemical changes in amphetamine sensitized rats: comparison of clozapine, haloperidol, and PNU-101387G
pp. 75-76(2)
Authors: Feldpausch D.L.; Meng Z.-H.; Needham L.M.; Stone M.P.; Svensson K.A.; Merchant K.M.

Induction of FOS protein immunoreactivity in the rat forebrain by the dopamine D3-selective constrained benzindole cis-8-OH-PBZI
pp. 76-76(1)
Authors: Fink-Jensen A.; Ludvigsen T.S.; Larsen P.J.; Scheideler M.; Korsgaard N.

Blockade of phencyclidine- and MK801-induced regional zif268 mRNA expression
pp. 76-76(1)
Authors: Gao X.-M.; Chen L.-W.; Tamminga C.A.

Developmentally specific disruptions of prepulse inhibition: sensitivity to antipsychotics
pp. 76-77(2)
Authors: Geyer M.A.; Bakshi V.; Braff D.L.; Swerdlow N.R.

Transmitter dysfunction and neural plasticity responses in limbic circuits in schizophrenia
pp. 77-77(1)
Authors: Glenthooj B.Y.; Hemmingsen R.P.

Ziprasidone: preclinical profile of a new antipsychotic agent
pp. 77-77(1)
Authors: Gunn K.P.; Heym J.; Zorn S.H.

Kainate receptor mRNA levels in rat limbic areas are differentially regulated by MK-801 treatment
pp. 77-78(2)
Authors: Healy D.J.; Meadow-Woodruff J.H.

A role for muscarinic cholinergic systems in the mechanisms of prepulse inhibition of the acoustic startle reflex and schizophrenia
pp. 78-78(1)
Authors: Jones C.K.; Shannon H.E.

Cortical regulation of subcortical dopamine release in rhesus monkeys with neonatal medial temporal-limbic lesions: implications for the developmental hypothesis of schizophrenia
pp. 78-78(1)
Authors: Kolachana B.S.; Saunders R.C.; Bachevalier J.; Weinberger D.R.

The effects of amphetamine, -MPT, and antipsychotics on dopamine D2 receptor occupancy. An EEDQ study
pp. 79-79(1)
Authors: Lahti R.A.; Tamminga C.A.

In vivo occupancy of D₂ dopamine receptors by D₃ receptor-selective drugs
pp. 79-79(1)
Authors: Levant B.; Bancroft G.N.; Selkirk C.M.; Vansell N.

In-vitro augmentation of NMDA receptor activity by typical and atypical antipsychotic drugs
pp. 79-79(1)
Authors: McCoy L.; Richfield E.K.

The nature of the action of amphetamine in the disrupted latent inhibition model of schizophrenia
pp. 80-80(1)
Authors: Moran P.M.; Peters S.L.; Young A.M.J.; Gray J.A.; Joseph M.H.

Blockade of the expression of behavioral sensitization to amphetamine by the selective dopamine D4 receptor antagonist, PNU-101387G
pp. 80-80(1)
Authors: Needham L.M.; Merchant K.M.

Aspartate containing neurons in the medial prefrontal cortex regulate transmission in the ventral tegmental area. A dual probe microdialysis study in the conscious rat
pp. 80-81(2)
Authors: O'Connor W.T.; Frantz K.

Comparison of intracortical versus intrastriatal infusions of D1 and D2 antagonists on extracellular dopamine levels in the rat
pp. 81-81(1)
Authors: Pehek E.A.; Schaldach M.A.

Effects of novel antipsychotic drugs on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test
pp. 81-81(1)
Author: Sams-Dodd F.

Potential pro-psychotic effect of subcortical serotonergic activity: augmentation of psychostimulant-induced dopamine release by mesostriatal 5-HT_2A receptors
pp. 81-82(2)
Authors: Schmidt C.J.; Taylor V.L.; Fadayel G.M.

The hyperlocomotion and dopamine release in the N. accumbens induced by systemic MK-801 is mediated by non-NMDA excitatory amino acid receptors in the ventral tegmental area
pp. 82-82(1)
Authors: Svensson T.H.; Mathe J.M.; Nomikos G.G.; Schilstrom B.

S(+)-N-n-propylnorapomorphine ([+]-NPA): a novel atypical antipsychotic with clozapine-like effects
pp. 82-82(1)
Authors: Tarazi F.I.; Yeghiayan S.K.; Baldessarini R.J.; Neumeyer J.L.

Further evidence for a role of the 5-HT_2A receptor in the mediation of antipsychotic activity
pp. 83-83(1)
Authors: Wadenberg M.-L.G.; Hicks P.B.; Young K.A.; Richter J.T.

Antipsychotic drugs interact with 5-HT_2A receptors to potentiate NMDA response in pyramidal cells of the medial prefrontal cortex
pp. 83-83(1)
Authors: Wang R.Y.; Arvanov V.L.; Magro P.

Effects of antipsychotics on brain biochemistry in the normal and hypoglutamatergic state--identification of antipsychotic mechanisms: a multivariate approach
pp. 83-84(2)
Authors: Waters N.; Waters S.H.; Hansson L.O.; Carlsson M.; Martin P.; Carlsson A.

Modulation of dopamine by norepinephrine in the prefrontal cortex
pp. 84-84(1)
Authors: Yamamoto B.K.; Mieskoski D.

The neurotensin agonist PD 149163 induces Fos protein expression in the prefrontal cortex: similarities to atypical antipsychotic drugs
pp. 84-84(1)
Authors: Young C.D.; Roth R.H.; Deutch A.Y.

Effect of chronic neuroleptic exposure on mRNA for the AMPA-A subunit of the AMPA glutamate receptor in postmortem human basal ganglia
pp. 85-85(1)
Authors: Bachus S.E.; Hyde T.M.; Herman M.M.; Kleinman J.E.

3orrelation between NMDA receptor mRNA in temporal cortex and antemortem cognitive impairment in schizophrenia
pp. 85-85(1)
Authors: de Belleroche J.; Humphries C.; Durnin A.; Mortimer A.; Hirsch S.

Comparison of NMDA receptor subtype (1, 2A, 2B, 2C, and 2D) mRNA expression in schizophrenic and control human postmortem brain tissue
pp. 85-86(2)
Authors: Buhler A.V.K.; Breese C.R.; Adams C.E.; Leonard S.

5-HT (serotonin) receptor gene expression in the aetiology, pathophysiology and pharmacotherapy of schizophrenia
pp. 86-86(1)
Authors: Burnet P.W.J.; Harrison P.J.

Dopamine D2 receptor mRNA expression in the hippocampal formation of schizophrenics
pp. 86-86(1)
Authors: Gurevich E.V.; Joyce J.N.

Gene expression markers of neuronal activity and plasticity in the cerebral cortex in schizophrenia
pp. 86-87(2)
Authors: Harrison P.J.; Eastwood S.L.

Measurement of RNA from 89 postmortem human brains; a multivariate statistical analysis of pre- and postmortem effects on the yields of GAPdH as measured by RT-PCR
pp. 87-87(1)
Authors: Johnston N.L.; Cervenak J.; Yolken R.H.; Shore A.; Torrey E.F.

Comparison of cDNA libraries from the brains of normal and schizophrenic individuals show that an unusually high number of novel sequences are present in the brain of the schizophrenic individual
pp. 87-87(1)
Authors: Johnston N.; Yolken R.; Torrey E.F.

Ionotropic glutamate receptor mRNA expression in schizophrenia
pp. 87-88(2)
Authors: Meador-Woodruff J.H.; Healy D.J.; Damask S.P.; Haroutunian V.; Powchik P.; Davidson M.; Davis K.L.; Watson S.J.

Serial analysis of gene expression of brain tissue from schizophrenia patient
pp. 88-88(1)
Authors: Sun Y.; Yolken R.H.

Quantitative analysis of dopamine D4 gene expression in control and schizophrenic post mortem tissue
pp. 88-88(1)
Authors: Stefanis N.; Bresnick J.; Kerwin R.; McAllister G.

Altered gene expression in the striatum following chronic neuroleptic therapy
pp. 89-89(1)
Authors: Rushlow W.; Naus C.G.; Flumerfelt B.A.; Rajakumar N.

Detection of viral particles in glial cells inoculated with brain tissue from individuals with schizophrenia and bipolar disease
pp. 89-89(1)
Authors: De I.; Melson L.M.; Brando L.; Yolken R.; Torrey E.F.

Pharmacogenetic factors in treatment-resistant schizophrenia: the role of CYP2D6 variants
pp. 89-89(1)
Authors: Aitchison K.J.; Munro J.; Wright P.; Chapman S.; Collier D.A.; Kerwin R.W.

Polymorphisms in the 5-HT2A receptor gene and promoter region associated with clozapine response
pp. 90-90(1)
Authors: Arranz M.J.; Munro J.; Sham P.; Zhao J.; Kirov G.; Sodhi M.; Spurlock G.; Owen M.; Collier D.A.; Kerwin R.

Regulation of the internalization of the 5HT_2A receptor in vitro
pp. 90-90(1)
Authors: Berry S.A.; Alsayegh L.; Roth B.L.

No association between a novel polymorphism in the 5-HT₄ receptor gene and response to clozapine
pp. 90-90(1)
Authors: Birkett J.T.P.; Collier D.A.; Munro J.; Arranz M.J.; Roberts G.W.; Price J.; Kerwin R.W.

Allelic variation of the 5-HT_2C receptor in psychosis
pp. 90-91(2)
Authors: Sodhi M.S.; Kirov G.; Aitchison K.J.; Arranz M.J.; Collier D.A.; Kerwin R.W.

Meta-analysis of association studies between schizophrenia and polymorphisms of the 5-hydroxytryptamine type 2A receptor gene
pp. 91-91(1)
Authors: Spurlock G.; Williams J.; McGuffin P.; Mallet J.; Nothen M.; Gill M.; Aschauer H.; Adolfsson R.; Macciardi F.; Owen M.J.

Lack of association between 5HT2A, 5HT2C, and D4 receptor gene polymorphisms and the deficit syndrome of schizophrenia
pp. 91-91(1)
Authors: Buchanan R.W.; Malhotra A.; Kirkpatrick B.; Goldman D.; Breier A.; Pickar D.

Childhood-early adolescence onset and adult onset schizophrenia: heterogeneity at the dopamine D3 receptor gene
pp. 92-92(1)
Authors: Maziade M.; Roy M.-A.; Martinez M.; Gauthier B.; Tremblay G.; Fournier C.; Bissonnette L.; Simard C.; Rouillard E.; Merette C.

The spatial expression pattern of the D4 gene in the human brain
pp. 92-92(1)
Authors: Mulcrone J.; Kerwin R.

D1 alleles predict clinical response to clozapine and corresponding brain metabolism: a genetic pet scan study
pp. 92-92(1)
Authors: Potkin S.G.; Kennedy J.; Badri F.; Yi J.; Masellis M.; Gulasekaram B.; Costa J.; Keator D.B.; Telford J.; Wu J.C.; Najafi A.

An investigation of the GLUR6 receptor gene (GRIK2) in schizophrenia
pp. 93-93(1)
Authors: Bolonna A.A.; Makoff A.J.; Collier D.A.; Kirov G.; Munro J.; Arranz M.J.; Kerwin R.W.

Is the polymorphic (CA)n repeat at the human cPLA2 locus associated with schizophrenia?
pp. 93-93(1)
Authors: Lee K.H.; Wei J.; Ramchand C.N.; Peet M.

APOE4 allele frequency is not increased in demented schizophrenics: a study of 116 patients with concomitant postmortem examination
pp. 93-93(1)
Authors: Powchik P.; Haroutunian V.; Greenberg D.; Altsteil L.; Purohit D.; Perl D.; Davidson M.

Apolipoprotein E and schizophrenia: association with clinical response to clozapine
pp. 93-94(2)
Authors: Royston M.C.; Bell R.; Collier D.; Kerwin R.W.; Roberts G.W.

Neurocognitive and social functioning in schizophrenia: A 2.5 year follow-up study
pp. 95-95(1)
Authors: Addington J.; Addington D.

Neuropsychological impairment in schizophrenia
pp. 95-95(1)
Authors: Albus M.; Hubmann W.; Sobizack N.; Wahlheim C.; Franz U.; Mohr F.

Substance abuse and neurocognitive function in schizophrenia
pp. 95-96(2)
Authors: Allen D.N.; Gilbertson M.W.; Seaton B.E.; Gurklis J.A.; Barry E.J.; van Kammen D.P.

Utility of WAIS-R short forms in schizophrenia
pp. 96-96(1)
Authors: Allen D.N.; Huegel S.G.; Seaton B.E.; Gurklis J.A.; Kelley M.E.; van Kammen D.P.

WAIS-R factor structure in schizophrenia
pp. 96-96(1)
Authors: Allen D.N.; Huegel S.G.; Gurklis J.A.; Kelley M.E.; van Kammen D.P.

Awareness deficits in neurological disorders and schizophrenia
pp. 96-97(2)
Authors: Amador X.F.; Barr W.B.; Economou A.; Mallin E.; Marcinko L.; Yale S.A.

Behavior problems in childhood and psychiatric outcomes in adulthood in the subjects of the New York High-Risk Project
pp. 97-97(1)
Authors: Amminger G.P.; Squires-Wheeler E.; Looser-Ott S.; Roberts S.; Pape S.; Rende R.; Rock D.; Erlenmeyer-Kimling L.

The ontogeny of schizophrenia
pp. 97-97(1)
Author: Asarnow R.F.

The 'benefits' of distractibility: mechanisms underlying increased stroop facilitation in schizophrenia
pp. 97-97(1)
Authors: Barch D.M.; Carter C.S.; Cohen J.D.; Hachten P.C.

Neuropsychological comparison of executive functions in first-episode schizophrenia and temporal lobe epilepsy
pp. 98-98(1)
Authors: Barr W.B.; Bilder R.M.; Goldman R.S.; Lieberman J.A.

Cognitively disorganized schizophrenia: a taxometric analysis of PANSS ratings
pp. 98-98(1)
Author: Bell M.

Positive and negative affect recognition in schizophrenia: a comparison of substance abuse and normal controls
pp. 98-98(1)
Authors: Bell M.; Lysaker P.; Bryson G.

Affect recognition in schizophrenia: a function of global impairment of a specific cognitive deficit
pp. 98-99(2)
Authors: Bryson G.; Bell M.; Lysaker P.

Inhibition of return in schizophrenia
pp. 99-99(1)
Authors: Bustillo J.; Gold J.; Thaker G.; Buchanan R.

Visual information processing deficits, the dorsal and ventral processing streams and clinical status in schizophrenia patients
pp. 99-99(1)
Authors: Cadenhead K.; Braff D.

A prospective cohort study of childhood cognitive deficits as precursors of schizophrenia
pp. 99-100(2)
Authors: Cannon T.D.; Bearden C.E.; Hollister J.M.; Hadley T.

Cognitive correlates of soft neurological signs in schizophrenia
pp. 100-100(1)
Authors: Chen E.Y.H.; Lam L.C.W.; Chen R.Y.L.; Nguyen D.G.H.

Recent hallucinators demonstrate abnormalities of central auditory processing
pp. 100-100(1)
Authors: Copolov D.; Headlam D.; Mackinnon A.; McKay C.; Thomas R.

The effects of ketamine on memory and other cognitive functions in schizophrenic patients and normal volunteers
pp. 100-100(1)
Authors: Corey P.K.; Lahti A.C.; LaPorte D.J.; Weiler M.A.; Warfel D.T.; Tamminga C.A.

Behavioral and electrophysiological correlates of attribution of malevolence to other people
pp. 101-101(1)
Authors: Debruille J.B.; Pelchat N.; Dubuc N.; Brodeur P.M.

Redundancy-associated deficit hypothesis for crossover is supported by change across trials in schizotypal males
pp. 101-101(1)
Authors: Dionisio D.P.; Sarkin A.J.; Hillix W.A.; Granholm E.L.

Why poor performance on the rivermead behavioural memory test in schizophrenia is indicative of a specific disease process
pp. 101-101(1)
Authors: Doody G.A.; Sanderson T.L.; Cunningham-Owens D.G.; Johnstone E.C.

Emotion recognition in first-episode schizophrenia: facial expression, affective prosody and emotion names
pp. 101-102(2)
Authors: Edwards J.; Pattison P.E.; Jackson H.J.; Wales R.J.

Inhibition of dominant response tendencies in schizophrenia
pp. 102-102(1)
Authors: Elvevaag B.; Duncan J.; McKenna P.J.

Primacy and recency on the Rey Auditory Verbal Learning Test (RAVLT): a comparison of normal controls and patients with schizophrenia
pp. 102-102(1)
Authors: Flashman L.A.; Torres I.J.; O'Leary D.S.; Tranel A.P.; Mosnik D.M.; Black J.; Andreasen N.C.

Longitudinal assessment of neuropsychiatric functioning in patients with schizophrenia and Alzheimer's disease
pp. 102-103(2)
Authors: Fleming K.; Nielson K.; Nilsson M.; Kalali A.; Sandman C.; Potkin S.G.; Bunney W.

Visual object perception in schizophrenia: further evidence for a selective impairment in semantic memory
pp. 103-103(1)
Authors: Gabrovska V.; Laws K.; McKenna P.J.

An examination of visual learning in patients with schizophrenia: evidence of a deficit in acquisition of novel information
pp. 103-103(1)
Authors: Glahn D.C.; Gur R.C.; Ragland J.D.; Cannon T.; Gur R.

The relationship of symptom dimensions and neuropsychological function in first episode and recent onset schizophrenia: a five year longitudinal study
pp. 103-104(2)
Authors: Gold S.; Arndt S.; Mosnik D.; Nopoulos P.; O'Leary D.S.; Andreasen N.C.

Effects of clozapine and haloperidol on explicit memory in treatment refractory patients
pp. 104-104(1)
Authors: Goldman R.S.; Bates J.A.; Pappadopulos E.; Bilder R.M.; Borenstein M.; Kane J.; Schooler N.; Marder S.

Impact of genetic vulnerability and obstetric factors on cognitive development up to age 7 in offspring high risk for psychosis
pp. 104-104(1)
Authors: Goldstein J.M.; Buka S.L.; Seidman L.J.; Zornberg G.; Hang L.; Denny L.; Goldin A.; Tsuang M.T.

Subgroups of patients with unilateral olfactory identification deficits in schizophrenia: different etiological profiles?
pp. 104-104(1)
Authors: Good K.P.; Martzke J.S.; Honer W.G.; Kopala L.C.

Effects of a computer-assisted attention training in schizophrenic patients
pp. 105-105(1)
Authors: Gorissen M.; Vollema M.; Kuipers T.; van Haren N.

Pupillary-response and visual-scanning indices of attentional impairment on the span of apprehension task in schizophrenia
pp. 105-105(1)
Authors: Granholm E.; Morris S.; Chock D.; Asarnow R.

Neuropsychological deficits in familial cerebellar degeneration: comparisons between psychotic and non-psychotic family members
pp. 105-105(1)
Authors: Gray N.S.; Pickup G.; Gilluley P.; Spence S.; Morton N.; James D.V.

Early visual processing deficits in remitted, unmedicated schizophrenic patients
pp. 105-106(2)
Authors: Green M.F.; Nuechterlein K.H.

Differentiation of orbito-frontal from dorsolateral functions and syndromes of schizophrenia
pp. 106-106(1)
Authors: Gruzelier J.; Green J.; Nagy A.

Rapid and gradual reconstitutive processes in schizophrenia
pp. 106-106(1)
Authors: Haas G.L.; Sweeney J.A.; Keshavan M.S.; Schooler N.R.

The relationship between conceptual ability and the use of effective coping strategies in individuals with schizophrenia
pp. 106-106(1)
Authors: Hall M.J.; Gordinier S.; Docherty N.

Learning and recall inefficiency in schizophrenia
pp. 107-107(1)
Authors: Harris J.G.; Benetto L.; Adler L.; Freedman R.

Cognitive decline in geriatric schizophrenic inpatients
pp. 107-107(1)
Authors: Harvey P.D.; Powchik P.; Mohs R.C.; Davidson M.

Wisconsin card sorting test and EEG changes in early psychosis
pp. 107-107(1)
Authors: Hofer H.; Merlo M.C.G.; Brenner H.D.

Estrogen levels relate to neuropsychological function in female schizophrenics
pp. 107-108(2)
Authors: Hoff A.L.; Wieneke M.; Horon R.; Blankfeld H.; Espinoza S.; Faustman W.O.; Kremen W.S.; Nordahl T.

Longitudinal neuropsychological findings from Stony Brook first episode study
pp. 108-108(1)
Authors: Hoff A.L.; Wieneke M.; Horon R.; Sakuma M.; Nordahl T.; DeLisi L.E.

Response time (RT) and the odds of making a correct choice
pp. 108-108(1)
Authors: Holcomb H.H.; Li-Wan C.; Lahti A.; Zuo Z.; Medoff D.; Caudill P.J.; Weiler M.; Tamminga C.A.

Cognitive function and psychotic symptoms in geriatric schizophrenia
pp. 108-109(2)
Authors: Howanitz E.; Hwang M.; Kaplan S.; Stern R.; Harvey P.D.; Mohs R.C.; Losonczy M.

Impact of benztropine on WAIS-R performance in schizophrenia
pp. 109-109(1)
Authors: Huegel S.G.; Allen D.N.; Gurklis J.A.; Kelley M.E.; van Kammen D.P.

Memory and executive function in first episode schizophrenia
pp. 109-109(1)
Authors: Hutton S.B.; Puri B.K.; Duncan L.-J.; Robbins T.W.; Barnes T.R.E.; Joyce E.M.

Schizophrenia impairs strategy generation but spares working memory
pp. 109-109(1)
Authors: Iddon J.L.; McKenna P.J.; Sahakian B.J.; Robbins T.W.

Temporal disintegration of visual perception in schizophrenia
pp. 110-110(1)
Authors: Izawa R.; Iwawaki A.; Ohta K.; Matsushima E.; Toru M.

Self-monitoring deficits in schizophrenia: autonoetic agnosia
pp. 110-110(1)
Authors: Keefe R.S.E.; Courtney M.; McEvoy J.M.

Cerebellar and cortical sensory dysfunction in schizophrenics and their relatives: hard neurologic signs
pp. 110-110(1)
Authors: Kinney D.K.; Yurgelun-Todd D.A.; Woods B.T.

Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man
pp. 110-111(2)
Authors: Kumari V.; Corr P.J.; Mulligan O.; Cotter P.A.; Checkley S.A.; Gray J.A.

Amphetamine and cognitive impairment in schizotypal personality disorder
pp. 111-111(1)
Authors: Kirrane R.; Harvey P.D.; Cornblatt B.; Bergman A.; Siever L.J.

Impaired olfactory identification ability and acuity in patients with schizophrenia and severe polydipsia: evidence for a degenerative process?
pp. 111-111(1)
Authors: Kopala L.C.; Good K.P.; Lopeter W.; Koczapski A.; Honer W.G.

Heterogeneity of Wisconsin card sorting test performance in schizophrenia: a factor analytic study
pp. 111-112(2)
Authors: Koren D.; Seidman L.J.; Harrison R.H.; Lyons M.J.; Kremen W.S.; Faraone S.V.; Goldstein J.M.; Caplan B.B.; Tsuang M.T.

Neuropsychological and symptom-based evidence of dysfunction in dorsolateral and orbital frontal systems in schizophrenia
pp. 112-112(1)
Authors: Kremen W.S.; Seidman L.J.; Oscar-Berman M.; Shore A.R.; Faraone S.V.; Tsuang M.T.

Comparison of hippocampal test performance in schizophrenic inpatients stabilized with typical antipsychotic medication and medication free
pp. 112-112(1)
Authors: LaPorte D.J.; Corey P.K.; Lahti A.C.; Tamminga C.A.

Effects of monetary reinforcement on verbal and visuospatial memory in schizophrenic subjects
pp. 112-113(2)
Authors: LaPorte D.; Lahti A.; Hagedorn H.; Corey T.; Tamminga C.

Detailed neuropsychological testing in treatment resistant and treatment responsive schizophrenia
pp. 113-113(1)
Authors: Lawrie S.; Rogers A.; O'Carroll R.; Ebmeier K.; Goodwin G.; Johnstone E.

Explicit and implicit memory functioning in first episode and chronic schizophrenic patients, in comparison to brain damaged amnesic patients
pp. 113-113(1)
Authors: Lussier I.; Stip E.; Coyette F.

Impairment in insight: evidence for an association with specific cognitive deficits in schizophrenia
pp. 113-114(2)
Authors: Lysaker P.; Bell M.; Bryson G.

Neural network modeling of initiation and inhibition in schizophrenia
pp. 114-114(1)
Authors: Mahurin R.; Velligan D.; Miller A.

Gender differences in the relationship between neuropsychological impairment and symptom dimensions in schizophrenia
pp. 114-115(2)
Authors: Malla A.K.; Norman R.M.G.; Morrison-Stewart S.; Williamson P.C.; Helmes E.; Cortese L.

Cognitive functioning and persistently high negative symptoms in chronic schizophrenia
pp. 115-115(1)
Authors: McGlashan T.H.; Quinlan D.; Glazer W.; Schuldberg D.

Relationship between plasma cortisol and cognitive function in schizophrenia
pp. 115-115(1)
Authors: McGurk S.R.; Lee M.; Meltzer H.Y.

Memory and negative symptoms predict role play performance in schizophrenic outpatients
pp. 115-116(2)
Authors: McKee M.B.; Smith T.E.; Hull J.W.; Walsh C.A.; Guttroff L.; Ellis R.A.

Neuropsychological deficits predict schizophrenic inpatients' attendance and participation in social skills training groups
pp. 116-116(1)
Authors: McKee M.B.; Hull J.W.; Smith T.E.

EEG changes and performance in span of apprehension in patients with early psychosis
pp. 116-116(1)
Authors: Merlo M.C.G.; Hofer H.; Brenner H.D.

Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: preliminary data
pp. 116-116(1)
Authors: Mitchell D.; Hagger C.; Wise A.L.; Schulz S.C.

Unilateral olfactory functioning in patients with schizophrenia
pp. 116-117(2)
Authors: Moberg P.J.; Turetsky B.I.; Doty R.; McKeown D.; Gur R.C.; Gur R.E.

Neurological soft signs and neuropsychological performance in first episode schizophrenia
pp. 117-117(1)
Authors: Mohr F.J.; Hubmann W.; Sobizack N.; Albus M.

Intellectual function and psychopathology in offspring at risk for schizophrenia
pp. 117-117(1)
Authors: Montrose D.M.; Dick E.; Pierri J.N.; Krinsky C.; Sweeney J.A.; Keshavan M.S.

Social functioning in relation to frontal lobe impairment
pp. 118-118(1)
Authors: Moore D.A.; Park S.; Born W.

Judging disorder in schizophrenia, concept and concept objectivity
pp. 118-118(1)
Authors: Morin D.C.; Decup A.M.; Morellini A.; Cochet N.C.; Lande H.; Poirier A.M.

Factor analysis of neuropsychological data in patients with schizophrenia and normal controls
pp. 118-118(1)
Authors: Mosnik D.M.; Gold S.M.; Tranel A.P.; O'Leary D.S.; Andreasen N.C.

The mechanisms of confabulation in schizophrenia
pp. 118-119(2)
Authors: Nathaniel-James D.A.; Foong J.; Frith C.D.

Psychoacoustic investigations in schizophrenia
pp. 119-119(1)
Authors: Nielzen S.; Olsson O.

Neuropsychological function in siblings of schizophrenics
pp. 119-119(1)
Authors: Olson S.C.; Nasrallah H.A.; Bornstein R.A.

Cognitive impairment and clinical symptoms in geriatric schizophrenic patients: differences associated with overall outcome
pp. 119-120(2)
Authors: Parrella M.; Howanitz E.; Powchik P.; Mohs R.C.; Harvey P.D.

Patterns of cognitive deficits associated with skin conductance in schizophrenia patients
pp. 120-120(1)
Authors: Perry W.; Felger T.; Braff D.

From preconscious to conscious processing--where does the abnormality lie in delusions?
pp. 120-120(1)
Authors: Peters E.; Day S.; Garety P.

Abnormal perception of simple and chimeric facial stimuli in schizophrenia: investigation of underlying attentional mechanisms using visual scan paths
pp. 120-121(2)
Authors: Phillips M.L.; David A.S.

Attention to threat in schizophrenia: investigation of the cognitive processes underlying paranoia using visual scan paths
pp. 121-121(1)
Authors: Phillips M.L.; David A.S.

'Theory of mind' and contextual processing in schizophrenia
pp. 121-121(1)
Authors: Pickup G.J.; Frith C.D.

Cognitive and clinical correlates of inaccurate affect recognition in schizophrenia
pp. 121-121(1)
Authors: Poole J.; Corwin F.; Vinogradov S.

Three dissociable components of frontal dysfunction in schizophrenia: relation to clinical course and psychosocial adaptation
pp. 122-122(1)
Authors: Poole J.; Vinogradov S.; Ober B.A.; Shenaut G.

Cognitive correlates of the deficit syndrome in geriatric schizophrenia
pp. 122-122(1)
Authors: Putnam K.M.; Davidson M.; Harvey P.D.

Associative learning, neuropsychological performance and psychophysiologic responses in inpatient and outpatient schizophrenics
pp. 122-123(2)
Authors: Renazco M.A.; Rawls T.; Smith M.; Kaiser S.; Davis M.; Russell I.S.; Young K.A.

Factors important for remediating the WCST in schizophrenia
pp. 123-123(1)
Authors: Russell S.L.; David A.S.

Unilateral assessment of olfactory deficits in schizophrenia
pp. 123-123(1)
Authors: Rupp C.; Ilmberger J.; Oberbauer H.; Wanko C.; Scholtz A.; Hinterhuber H.

The nature of impairments on tasks of executive function in patients with schizophrenia
pp. 124-124(1)
Authors: Rushe T.M.; Woodruff P.W.R.; Murray R.M.; Morris R.G.

'Do different insight scales measure the same thing?'
pp. 124-124(1)
Authors: Sanz M.; Constable G.; Lopez-Ibor I.; Kemp R.; David A.

Ocular, cognitive and social interference in schizophrenia
pp. 124-124(1)
Authors: Schooler C.; Roberts B.; Zahn T.; Cohen R.

Can self-experienced neuropsychological deficits indicate a psychosis proneness? Results of an 8 years prospective follow-up study
pp. 124-124(1)
Authors: Schultze-Lutter F.; Steinmeyer E.M.; Klosterkotter J.

Self-experienced neuropsychological deficits in the mentally retarded as a possible cause of schizophrenia proneness
pp. 124-125(2)
Authors: Schultze-Lutter F.; Steinmeyer E.M.; Klosterkotter J.

Effect of nifedipine on motor skill learning in schizophrenia
pp. 125-125(1)
Authors: Schwartz B.; Fay-McCarthy M.; Kendrick K.; Rosse R.; Deutsch S.

Delayed and object alternation deficits in schizotypal personality disorder
pp. 125-125(1)
Authors: Seidman L.J.; Voglmaier M.M.; Niznikiewicz M.; Dickey C.C.; Sollinger J.; Rhoads R.; Shenton M.E.; McCarley R.W.

The use of schemas in understanding schizophrenic reasoning
pp. 125-126(2)
Authors: Simpson J.; Done J.

Symptom and neuropsychological determinants of insight in schizophrenia
pp. 126-126(1)
Authors: Smith T.E.; Hull J.W.; Walsh C.A.; Felger T.E.; Hedayat-Harris A.; Raymond S.C.; Weiss K.A.; Pappas Schattman S.S.

Effects of schizophrenia and complex partial epilepsy on memory
pp. 126-126(1)
Authors: Stone W.S.; Seidman L.J.; Jones R.; Harrison R.H.; Mirsky A.

A comparison of the neuropsychological functioning of substance abusing and non-substance abusing schizophrenia subjects
pp. 126-127(2)
Authors: Thomas S.M.; Scheller-Gilkey G.; Wiley J.

Implicit motor learning and memory in schizophrenia
pp. 127-127(1)
Authors: Thoroughman K.A.; Weiler M.A.; Lahti A.C.; Tamminga C.A.; Holcomb H.H.

Poor perception of nonverbal social-emotional cues in relatives of schizophrenic patients: an attentional deficit?
pp. 127-127(1)
Authors: Toomey R.; Seidman L.J.; Lyons M.J.; Faraone S.V.; Tsuang M.T.

The relationship of IQ to source monitoring errors in schizophrenia
pp. 127-127(1)
Authors: Vinogradov S.; Poole J.H.; Willis-Shore J.; Ober B.A.; Shenaut G.K.

Executive and attentional functions mediate accelerated forgetting in schizophrenia
pp. 128-128(1)
Authors: Willson D.F.; Bilder R.M.; Christensen B.K.; Lieberman J.A.

Cognitive vulnerability factors in chronic schizophrenia: are there two kinds? response inhibition vs planning
pp. 128-128(1)
Authors: Wykes T.; Reeder C.; Corner J.

The effects of D-amphetamine on working memory and language deficits in schizophrenia
pp. 129-129(1)
Authors: Barch D.M.; Carter C.S.; Braver T.S.; Cohen J.D.

Behavioral assessment of frontal/cingulate attention deficits in schizophrenia
pp. 129-129(1)
Authors: Belger A.; McNulty A.-M.; Krystal J.H.

Behavioral dissociation of working memory and selective attention functions in schizophrenia
pp. 129-130(2)
Authors: Belger A.; Taqqu Y.; Krystal J.H.

Disturbed language processing disorganization, and attentional impairment in schizophrenia
pp. 130-130(1)
Authors: Carter C.S.; Barch D.; Cohen J.D.

Context processing disturbances in schizophrenia: empirical test of a theoretical model
pp. 130-130(1)
Authors: Cohen J.D.; Barch D.M.; Carter C.S.; Servan-Schreiber D.

Language and thought disorder in schizophrenia: cognitive neuropsychological approaches
pp. 130-130(1)
Author: David A.S.

Comparative affective reactivity of different types of communication disturbances in schizophrenia
pp. 131-131(1)
Authors: Docherty N.M.; Hebert A.S.; Hall M.J.; Gordinier S.W.

Attentional impairment and specific subtypes of communication deviance in schizophrenic patients
pp. 131-131(1)
Authors: Eckert S.L.; Velligan D.I.; Mahurin R.K.; Miller A.L.; Bow-Thomas C.C.

Response inhibition in formal thought disorder
pp. 131-131(1)
Authors: Gorissen M.E.E.; van Haren N.E.M.; Vollema M.G.

Semantic priming, overinclusiveness and formal thought disorder
pp. 131-132(2)
Authors: Gorissen M.E.E.; Nielen M.M.A.

Is thought disorder in schizophrenia a function of loss of context and impaired working memory?
pp. 132-132(1)
Authors: Harrow M.; Rappole K.; Sands J.R.; Jobe T.H.; Martin E.M.

Voluntary and involuntary shifts of attention in schizophrenia
pp. 132-132(1)
Authors: Hill J.M.; Sweeney J.A.; Haas G.L.

Selective attention asymmetries: evidence for a broad scope of left hemisphere attentional dysfunction in schizophrenia
pp. 132-133(2)
Authors: Huston T.A.; Carter C.S.; Behrmann M.

Thought disorder in subjects with schizophrenia spectrum disorders
pp. 133-133(1)
Authors: Koistinen P.; Wahlberg K.-E.; Anias-Tanner H.; Keskitalo P.; Tarvainen T.; Moring J.; Hakko H.; Wynne L.C.; Tienari P.

Reduced sensitivity to context in schizophrenic thought disorder: evidence from online monitoring for words in linguistically-anomalous sentences
pp. 133-133(1)
Authors: Kuperberg G.R.; McGuire P.K.; Tyler L.K.; David A.S.

Semantic priming N4 modulation in formal thought disordered schizophrenics
pp. 133-134(2)
Authors: Laurent J.-P.; Passerieux C.; Lafont-Rapnouil S.; Baribeau J.; Hardy-Bayle M.-C.

Language cohesion in preschizophrenic children
pp. 134-134(1)
Authors: Leinonen E.; Done D.J.; Sinclair C.; Crow T.J.

Language disorder and formal thought disorder in schizophrenia: using the neuropsychological case study approach to explore the relationship
pp. 134-134(1)
Authors: Oh T.; McCarthy R.A.; Giles E.; McKenna P.J.

Attention deficits in adolescents with schizophrenia or ADHD
pp. 134-134(1)
Authors: Oie M.; Rund B.R.; Sundet K.

Attentional inhibition and clinical symptoms in schizophrenia patients
pp. 134-135(2)
Authors: Park S.; Puschel J.; Minor K.; Ragin A.; Hauser B.; Hell D.

Working memory performance in relation to clinical symptoms in schizophrenia patients: a 4-month follow-up study
pp. 135-135(1)
Authors: Park S.; Puschel J.; Moore D.A.; Ragin A.; Hooker C.; Hauser B.; Hell D.

Structural and functional correlates of working memory and olfactory identification in schizotypal subjects
pp. 135-135(1)
Authors: Park S.; Raine A.; Lencz T.; Bihrle S.; LaCasse L.

A dynamic threshold semantic neural network (DTSNN): simulations of thought disorders in schizophrenia
pp. 135-135(1)
Authors: Peled A.; Geva A.B.

Effect of stimulus meaningfulness on CPT performance
pp. 136-136(1)
Authors: Roberts B.; Schooler C.

Working memory is spared in schizophrenia
pp. 136-136(1)
Authors: Rubinsztein J.; McKenna P.J.; Baddeley A.D.

Semantic priming in deluded schizophrenics
pp. 136-136(1)
Authors: Rossell S.L.; Shapleske J.; David A.S.

Neuropsychological evidence of a deficit in switching attention in schizophrenia--a replication study
pp. 136-137(2)
Authors: Smith G.L.; Large M.M.; O'Sullivan B.T.; Kavanagh D.J.; Karayanidis F.; Michie P.T.

A cognitive neuroscience view on formal thought disorder
pp. 137-137(1)
Authors: Spitzer M.; Maier S.; Weisbrod M.

Working memory deficits in schizophrenia: dysfunction in multiple systems, not in the central executive
pp. 137-137(1)
Authors: Spindler K.A.; Sullivan E.V.; Menon V.; Lim K.O.; Pfefferbaum A.

The working memory construct: convergent and discriminant validity
pp. 137-138(2)
Authors: Strauss M.E.; Jaskiw G.; Smith R.W.; Rizzuto L.

Spatial and verbal working memory deficits in schizophrenia
pp. 138-138(1)
Authors: Taylor S.F.; Smith E.E.; Jonides J.; Decker L.; Smet I.C.; Tandon R.

Communication deviance of the adoptive parents and poor cognitive functioning of the adoptees
pp. 138-138(1)
Authors: Wahlberg K.-E.; Wynne L.C.; Keskitalo P.; Koistinen P.; Tarvainen T.; Hakko H.; Lahti I.; Laksy K.; Moring J.; Naarala M.; Sorri A.; Seitamaa M.; Tienari P.

Thalamic volumes in schizophrenia: failure to replicate reduced volume
pp. 139-139(1)
Authors: Arciniegas D.; Sheeder J.; Rojas D.; Teale P.; Reite M.

Reversed planum temporale asymmetry in schizophrenia--a replication study
pp. 139-139(1)
Authors: Barta P.E.; Pearlson G.D.; Pulver A.E.; Powers R.E.; Casanova M.; Frangou S.; Petty R.G.

Neuroanatomic abnormalities in the psychoses: diagnostic specificity or severity spectrum?
pp. 139-140(2)
Authors: Bilder R.M.; Bogerts B.; Wu H.; Strous R.; Lee H.; Lieberman J.; Woerner M.

Shape deformity in schizophrenia: a MRI morphometric study
pp. 140-140(1)
Authors: Buckley P.F.; Dean D.; Friedman L.; Kwon D.; Bookstein F.L.; Lewin J.S.; Kamath J.; Lys C.

Regional brain morphology in siblings discordant for schizophrenia: a magnetic resonance imaging study
pp. 140-140(1)
Authors: Cannon T.D.; Huttunen M.; Standertskjold-Nordenstam C.-G.; Salonen O.; Valanne L.; Lonnqvist J.

Point distribution models and gyrification in schizophrenia
pp. 140-140(1)
Authors: Caunce A.; Hopkins R.S.; Taylor C.; Lewis S.W.

Effect of neuroleptic treatment on post-mortem rodent striatal volumes
pp. 140-141(2)
Authors: Chakos M.; Lee H.; Bilder R.; Zhao M.; Tamminga C.

Reduced anterior hippocampal volumes are associated with alternating response patterns in first episode schizophrenia
pp. 141-141(1)
Authors: Crandall D.T.; Szeszko P.R.; Bilder R.M.; Strous R.; Lieberman J.A.

A comparison of the hippocampus in schizophrenia and control subjects using automated methods for neuromorphometry
pp. 141-141(1)
Authors: Csernansky J.G.; Haller J.W.; Banerjee A.; Lei W.; Joshi S.; Christensen G.E.; Gado M.; Vannier M.W.; Miller M.I.

Brain structural change over time after a 1st episode of schizophrenia
pp. 141-142(2)
Authors: DeLisi L.E.; Hoff A.L.; Tew W.; Sakuma M.; Grimson R.

Landmark shape in schizophrenia: regional neuroanatomic correlates
pp. 142-142(1)
Authors: DeQuardo J.R.; Rajaprabhakaran R.; Bookstein F.L.; Brunberg J.A.; Tandon R.

Regional cerebellar volume deficits in schizophrenia, alcoholism and schizophrenia with alcohol comorbidity
pp. 142-143(2)
Authors: Deshmukh A.; Sullivan E.V.; Mathalon D.H.; Desmond J.E.; Lim K.O.; Pfefferbaum A.

Abnormal signal intensity of corpus callosum in schizophrenia
pp. 143-143(1)
Authors: Dick E.L.; Kotwal R.; Rosenberg D.R.; Bagwell W.W.; Kisler T.; Sweeney J.; Pettegrew J.W.; Keshavan M.S.

MRI and cognitive correlates in schizotypal personality disorder
pp. 143-143(1)
Authors: Dickey C.C.; Voglmaier M.M.; Shenton M.E.; Niznikiewicz M.; Seidman L.J.; Fischer I.A.; Teh E.; Rhoads R.A.; McCarley R.W.

Gender dependence of prefrontal volume in schizophrenia
pp. 143-144(2)
Authors: Doyle R.G.; Sheeder J.; Rojas D.C.; Teale P.; Simon J.; Reite M.

Cortical surface in schizophrenic patients and controls: MRI, 3-D reconstruction and in vivo morphometry
pp. 144-144(1)
Authors: Falkai P.; Schormann T.; Steinmetz H.; Palomero-Gallagher N.; Honer W.G.; Zilles K.

MRI measurements in adolescents with schizophrenia and bipolar disorder
pp. 144-144(1)
Authors: Findling R.L.; Friedman L.; Swales T.P.; Swift D.K.; Wise A.; Schulz S.C.

A study of head size in adult patients with schizophrenia
pp. 144-145(2)
Authors: Friedman L.; Jesberger J.A.; Swales T.; Rakow R.; Ward K.; Pi D.; Schulz S.C.; Buckley P.F.

Prediction of intracranial volume from post-mortem head, stature and body frame measurements: influences of gender, race, and implications for schizophrenia research
pp. 145-145(1)
Authors: Friedman L.; Cerny C.; Wiechers I.; Jellema L.; Latimer B.; Schulz S.C.; Buckley P.F.

Volumetric magnetic resonance imaging analysis of the cingulate cortex and corpus callosum in schizophrenia
pp. 145-145(1)
Authors: Garnett M.L.; Semple W.E.; Konicki P.E.; Muswick G.J.; Goyer P.F.

Premorbid functioning, symptoms and response in expanding vs non-expanding ventricle schizophrenic psychoses
pp. 145-146(2)
Authors: Garver D.L.; Christensen J.D.; Nair T.R.; Holcomb J.; Kingsbury S.J.

Can hyponatremic schizophrenics yield clues to the pathophysiology of psychosis?
pp. 146-146(1)
Author: Goldman M.B.

Sex differences in structural brain abnormalities in schizophrenia: frontal versus posterior brain regions
pp. 146-146(1)
Authors: Goldstein J.M.; Seidman L.J.; Goodman J.; Makris N.; Kennedy D.; Hoge E.; Caviness V.; Faraone S.V.; Tsuang M.T.

Verbal memory and regional brain volume in schizophrenia: MRI and neuropsychological measures
pp. 146-147(2)
Authors: Goodman J.M.; Seidman L.J.; Goldstein J.M.; Faraone S.V.; Hoge E.; Makris N.; Kennedy D.N.; Caviness V.S.; Tsuang M.T.

Uncoupling between tissue volume and metabolic rates in schizophrenia
pp. 147-147(1)
Authors: Gur R.C.; Mozley L.H.; Turetsky B.I.; Mozley P.D.; Gur R.E.

Asymmetry of the middle cranial fossa in schizophrenia, temporal lobe epilepsy and controls
pp. 147-147(1)
Authors: Hamersley S.P.; Wang E.; Regis E.; Lang D.J.; Beach T.G.; Smith G.N.; Lapointe J.S.; Falkai P.; Honer W.G.

Reduced white matter volume in schizophrenia: a controlled 3D MR segmentation study
pp. 147-148(2)
Authors: Hemmingsen R.; Madsen A.; Ring P.; Lassen A.

MRI and ERP abnormalities in first episode schizophrenia and affective psychosis
pp. 148-148(1)
Authors: Hirayasu Y.; Shenton M.E.; Salisbury D.F.; Fischer I.A.; Dickey C.D.; Arakaki H.; Yurgelun-Todd D.A.; Tohen M.; McCarley R.W.

Development of a temporal lobe task in schizophrenia
pp. 148-148(1)
Authors: Howanitz E.; Losonczy M.; Hwang M.; Schaefer C.; Sison C.

Sex and diagnostic effects on corpus callosum morphology
pp. 148-149(2)
Authors: Karp P.E.; Houwei W.; Jian H.; Bilder R.

Reduction of nucleus accumbens volume in schizophrenia: a volumetric MRI-study
pp. 149-149(1)
Authors: Kromkamp M.; Baare W.F.C.; Pol H.E.H.; van der Linden J.A.; Kahn R.S.

Morphometry of cerebellar vermis in chronic schizophrenia and autism: MRI evidence of developmental etiology
pp. 149-149(1)
Authors: Kilman A.; Reeve A.; Cooperman R.B.; Lesnik P.G.; Ciesielski K.T.

Brain anatomic magnetic resonance imaging in pediatric patients with psychosis NOS
pp. 149-150(2)
Authors: Kumra S.; Giedd J.; Jacobsen L.; McKenna K.; Frazier J.; Gordon C.; Lenane M.; Hamburger S.; Smith A.; Rapoport J.

The MRI study of cavum septi pellucidi in schizophrenia and affective disorder
pp. 150-150(1)
Authors: Jun S.K.; Shenton M.E.; Hirayasu Y.; Fischer I.A.; McCarley R.W.

Sylvian fissure and middle cranial fossae asymmetries in families with schizophrenia
pp. 150-150(1)
Authors: Lang D.J.; Bassett A.S.; Falkai P.; Smith G.N.; Lapointe J.S.; Honer W.G.

How abnormal is the brain in schizophrenia?--A systematic and quantitative review of volumetric magnetic resonance imaging studies
pp. 150-151(2)
Authors: Lawrie S.; Abukmeil S.

MRI landmark shape analysis of neuroanatomy in first-episode schizophrenia
pp. 151-151(1)
Authors: Lencz T.; Redmond M.P.; Bookstein F.L.; Houwei W.; Bilder R.M.; Ashtari M.; Lieberman J.A.

Corpus callosum, behavioral lateralization, and schizophrenia
pp. 151-151(1)
Authors: Lewine R.; Levine L.; Scheller-Gilkey G.; Shurett R.; Caudle J.

Clinical symptoms and MRI abnormalities in schizophrenia and in epilepsy
pp. 151-152(2)
Authors: Marsh L.; Sullivan E.; Spears S.; Sung T.; Lim K.; Morrell M.; Pfefferbaum A.

Structural MRI abnormalities in schizophrenia: a comparison of state hospital and veterans hospital patients
pp. 152-152(1)
Authors: Marsh L.; Lim K.; Hoff A.; Harris D.; Beal M.; Minn K.; Faustman W.; Csernansky J.; Sullivan E.; Pfefferbaum A.

Longitudinal analysis of MRI brain volumes in schizophrenia
pp. 152-152(1)
Authors: Mathalon D.H.; Sullivan E.V.; Lim K.O.; Pfefferbaum A.

A structural MRI study of schizophrenia and epilepsy
pp. 152-153(2)
Authors: Mellers J.D.C.; Toone B.K.; Lishman W.A.

Progressive ventricular enlargement and neurodegerative schizophrenia
pp. 153-153(1)
Authors: Nair T.; Christensen J.; Kumar N.; Mayhew E.; Garver D.

Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study
pp. 153-153(1)
Authors: Nelson M.D.; Saykin A.J.; Flashman L.A.; Riordan H.J.

Incidence of enlarged cavum septi pellucidi in childhood onset schizophrenia vs healthy controls
pp. 153-154(2)
Authors: Nopoulos P.; Rapoport J.; Giedd J.; Andreasen N.

Structural and functional imaging in catatonia
pp. 154-154(1)
Authors: Northoff G.; Waters H.; Diekmann S.; Braus D.; Leschinger A.; Bogerts B.

Brain morphology in down syndrome and schizophrenia
pp. 154-154(1)
Authors: Pearlson G.D.; Barta P.E.; Aylward E.H.; Breiter S.; Warren A.C.

Accelerated increase brain ventricular volume at 2-year rescan for childhood onset schizophrenics
pp. 154-154(1)
Authors: Rapoport J.L.; Giedd J.; Alaghband-Rad J.; Jacobsen L.; Kumra S.; Lenane M.

The effect of cumulative neuroleptic exposure on caudate and putamen volumes
pp. 154-155(2)
Authors: Rodriguez R.; Flaum M.; Nopoulos P.

Talairach-based MRI analysis in first episode schizophrenia
pp. 155-155(1)
Authors: Roy P.D.; Zipursky R.B.; Mikulis D.E.

Application of a nearly automatic image scale space linking scheme to segment gray and white matter and intracranial volumes on MR images
pp. 155-155(1)
Authors: Schnack H.G.; Hulshoff Pol H.E.; Staal W.; Vincken K.; Niessen W.M.; Viergever M.A.; Kahn R.S.

Structural MRI studies of first-degree relatives of schizophrenic patients
pp. 155-155(1)
Authors: Seidman L.J.; Faraone S.V.; Goldstein J.M.; Matsuda G.; Hoge E.; Toomey R.; Bates J.F.; Makris N.; Kennedy D.N.; Caviness V.S.; Tsuang M.T.

Loss of sylvian fissure asymmetry in schizophrenic auditory hallucinators using structural MRI
pp. 156-156(1)
Authors: Shapleske J.; Rossell S.L.; Woodruff P.W.R.; David A.S.

Methodological considerations of measuring the planum temporale
pp. 156-156(1)
Authors: Shapleske J.; Rossell S.L.; Woodruff P.W.R.; David A.S.

Corpus callosum and schizophrenia: a five year follow-up
pp. 156-156(1)
Authors: Shurett R.B.; Lewine R.R.J.; Caudle J.

Comparison of striatal volumes in schizophrenic patients with and without eye tracking disorder
pp. 156-157(2)
Authors: Sjodin L.E.; Ross D.E.; Vladar K.; Buchanan R.W.; Thaker G.K.; Holcomb H.H.; Tamminga C.A.

Progressive brain changes and age at onset of illness in schizophrenia
pp. 157-157(1)
Authors: Smith G.N.; Kopala L.C.; Lapointe J.S.; MacEwan G.W.; Altman S.; Flynn S.W.; Schneider T.; Falkai P.; Honer W.G.

Stereological estimation of gyrification index and related measures of cortical folding from mr data in schizophrenia
pp. 157-157(1)
Authors: Stefan M.D.; Sharma T.; Ellison Z.; Murray R.; Everall I.

Pregnancy and birth complications (PBC)--associated hippocampal volume reduction in sporadic schizophrenia
pp. 157-158(2)
Authors: Stefanis N.; Yakeley J.; Frangou S.; Sharma T.; O'Connell P.; Morgan K.; Murray R.

Parcellation of the frontal lobes in first-episode schizophrenia
pp. 158-158(1)
Authors: Szeszko P.; Lencz T.; Bilder R.; Redmond M.; Wu H.; Lieberman J.

Temporal origin of cerebral structural abnormalities in schizophrenia: associations with second trimester dermatoglyphic ridge counts
pp. 158-158(1)
Authors: van Os J.; Woodruff P.; Fananas L.; Shuriquie N.; Howard R.; Murray R.

Reduced frontal volume, frontal-temporal connectivity, and hippocampal volume is associated with the deficit syndrome in schizophrenia
pp. 158-159(2)
Authors: Ventura J.; Bartzokis G.; Nuechterlein K.H.; Subotnik K.L.; Raja P.

Prefrontal cortex in schizophrenia: a magnetic resonance imaging study using anatomically relevant landmarks
pp. 159-159(1)
Authors: Vladar K.; Buchanan R.W.; Carpenter W.T.; Barta P.E.; Pearlson G.D.

MRI-determined brain volumes and schizotypal characteristics in subjects with sex chromosome anomalies and matched controls
pp. 159-159(1)
Authors: Warwick M.M.; Best J.J.K.; Johnstone E.C.; Kestelman I.N.; Sandler R.

Change in basal ganglia volume across time in patients with schizophrenia: effects of atypical vs. typical neuroleptics
pp. 159-160(2)
Authors: Westmoreland P.; Nopoulos P.C.; Arndt S.V.; Bailey J.; Andreasen N.C.

Obstetric complications and brain MRI findings in schizophrenia
pp. 160-160(1)
Authors: Woerner M.G.; Gunduz H.; Alvir J.M.J.; Bilder R.; Lieberman J.A.

Mapping of gray matter changes in schizophrenia
pp. 160-160(1)
Authors: Wright I.; Ellison Z.; Sharma T.; Friston K.; Murray R.; McGuire P.

Absence of overall cortical and subcortical volume differences among major mental disorders
pp. 160-161(2)
Authors: Houwei W.; Young L.; Bogerts B.; Lieberman J.A.; Bilder R.M.

Shape analysis of hippocampus in schizophrenia
pp. 161-161(1)
Authors: Houwei W.; Strous R.; Bilder R.M.; Alvir J.; Ashtari M.

Volumetric MRI study of first episode schizophrenia
pp. 161-161(1)
Authors: Zipursky R.B.; Lambe E.K.; Kapur S.; Mikulis D.J.

Activation of prefronal cortex by the representation and maintainance of context information
pp. 163-163(1)
Authors: Barch D.M.; Braver T.S.; Nystrom L.; Noll D.C.; Cohen J.D.

Positron emission tomography in schizophrenics treated with atypical and typical neuroleptics
pp. 163-163(1)
Authors: Buchsbaum M.; Hazlett E.; Bark N.; Gupta A.; Fallon J.; Guich S.; Haznedar M.

Proton magnetic resonance spectroscopy and aberrant neurodevelopment: frontal lobe metabolism in adolescent-onset schizophrenia and in autism
pp. 163-163(1)
Authors: Buckley P.F.; Lys C.; Findling R.; Schulz S.C.; Min X.; Thian N.

Abnormal cortical physiology associated with selective attention dysfunction in schizophrenia
pp. 164-164(1)
Authors: Carter C.S.; Mintun M.; Cohen J.D.

How many subjects? A Monte Carlo bootstrap simulation for functional imaging
pp. 164-164(1)
Authors: Chen L.-W.; Zuo Z.; Medoff D.; Holcomb H.H.; Lahti A.C.; Tamminga C.A.

Pet correlational studies of auditory stimulation and auditory hallucinations in schizophrenia patients
pp. 164-164(1)
Authors: Copolov D.L.; Egan G.F.; Wong M.T.H.; Maruff P.; Tochon-Danguy H.J.; Chan J.G.; Waite M.

Overt and covert verbal fluency: an fMRI comparison
pp. 164-165(2)
Authors: Curtis V.; Bullmore E.; Brammer M.; Grasby P.; Murray R.; McGuire P.

Reduced cerebral response to verbal fluency tasks in schizophrenia: an fMRI investigation
pp. 165-165(1)
Authors: Curtis V.; Bullmore E.; McGuire P.; Brammer M.; Simmons A.; Grasby P.; Sharma T.; Murray R.

Relationship between symptom dimensions and cerebral blood flow in schizophrenia as assessed by ¹⁵H₂O P.E.T.
pp. 165-165(1)
Authors: Flaum M.; O'Leary D.S.; Johnson D.; Arndt S.; Cizadlo T.; Hichwa R.; Andreasen N.C.

Disorganisation and frontal blood flow measured by 99mTc-HMPAO
pp. 165-165(1)
Authors: Gracia R.; Aguilar E.J.; Cejas R.; Herreros O.; Diaz A.; Hernandez J.; Fernandez L.

SPECT and schizophrenia: a comparison between medicated and non-medicated patients
pp. 166-166(1)
Authors: Gracia R.; Herreros O.; Cejas R.; Diaz A.; Fernandez L.; Hernandez J.; Aguilar E.J.

Out loud vs. silent verbal fluency: a FMRI study
pp. 166-166(1)
Authors: Gruber S.A.; Baird A.A.; Sherwood A.R.; Renshaw P.F.; Yurgelun-Todd D.A.

Ketamine induced cerebellar-cingulate rCBF correlations and rCBF patterns in normal volunteers (NV) and schizophrenic patients (SZ)
pp. 166-166(1)
Authors: Holcomb H.H.; Lahti A.; Medoff D.; Zuo Z.; Weiler M.; Corey P.; Warfel D.; Tamminga C.A.

Cerebral glucose metabolism in childhood onset schizophrenia
pp. 166-167(2)
Authors: Jacobsen L.K.; Hamburger S.D.; Van Horn J.D.; Vaituzis A.C.; McKenna K.; Frazier J.A.; Gordon C.T.; Lenane M.C.; Rapoport J.L.; Zametkin A.J.

'Typical' vs. 'atypical': lessons from pet studies of 5-HT₂ and D₂ occupancy of antipsychotics
pp. 167-167(1)
Authors: Kapur S.; Remington G.; Jones C.; Houle S.; Zipursky R.

Blood flow activation differences during an auditory task in schizophrenic patients with and without primary negative symptoms
pp. 167-167(1)
Authors: Lahti A.C.; Holcomb H.H.; Carpenter W.T.; Zhao M.; Buchanan R.W.; Tamminga C.A.

Regional correlations between ketamine-induced actions on psychosis and regional cerebral blood flow (rCBF)
pp. 167-168(2)
Authors: Lahti A.C.; Holcomb H.H.; Weiler M.A.; Zhao M.; Medoff D.; Chen L.-W.; Tamminga C.A.

The functional anatomy of language processing: towards an understanding of schizophrenic thought disorder
pp. 168-168(1)
Authors: Kuperberg G.R.; McGuire P.K.; Bullmore E.T.; Brammer M.J.; Wright I.C.; Williams S.C.R.; Simmons A.; David A.S.

Functional connectivity during word generation in schizophrenia
pp. 168-168(1)
Authors: Liddle P.F.; Passmore M.; Friston K.J.; Frith C.D.

Impaired secondary and tertiary olfactory processing in schizophrenia: a spect study of neuroactivation with the upsit
pp. 168-169(2)
Authors: Malaspina D.; Lignelli A.; Pererra G.; Marshall R.; Gorman J.; Van Heertum R.

Brain activity during stimulus independent thought
pp. 169-169(1)
Authors: McGuire P.; Paulesu E.; Frackowiak R.; Frith C.

A pet study of formal thought disorder
pp. 169-169(1)
Authors: McGuire P.; Quested D.; Spence S.; Murray R.; Frith C.; Liddle P.

The methodological effects of repeated [15]O pet blood flow scans in schizophrenic and normal volunteers during rest and task performance
pp. 169-169(1)
Authors: Medoff D.R.; Holcomb H.H.; Lahti A.C.; Zhao Z.; Chen L.-W.; Tamminga C.A.

An fMRI study of verbal working memory in schizophrenia
pp. 169-170(2)
Authors: Mellers J.D.C.; Wykes T.; Bullmore E.; Williams S.C.R.; Simmons A.; Reeder C.; Corner J.; Brammer M.

Regional cerebral glucose metabolic differences via the PET-600 in paranoid schizophrenics performing a stroop task
pp. 170-170(1)
Authors: Nordahl T.E.; Kusubov N.; Carter C.; Kraft L.; Salamat S.; Baldo J.; Robertson L.

A pet study of auditory attention deficits in patients with schizophrenia: a replication and extension of previous findings
pp. 170-170(1)
Authors: O'Leary D.S.; Andreasen N.C.; Hurtig R.R.; Arndt S.; Flaum M.A.; Hichwa R.D.

Functional neuroanatomy of working memory and attention in schizophrenia
pp. 170-171(2)
Authors: O'Sullivan B.T.; Smith G.L.; Woodham B.L.; Large M.M.; Kavanagh D.J.; Watson J.D.; Michie P.T.; Karayanidis F.

Verbal fluency (VF) and brain evoked potentials in schizophrenia
pp. 171-171(1)
Authors: Robins N.M.; Chen A.C.N.; Soni S.D.; Deakin J.F.W.

Sex-specificity of cerebral asymmetry in heschl's gyrus in paranoid schizophrenia
pp. 171-172(2)
Authors: Rojas D.; Teale P.; Sheeder J.; Simon J.; Reite M.

Functional neuroanatomy of smooth pursuit eye movements in normal controls and schizophrenic patients
pp. 172-172(1)
Authors: Ross D.E.; Holcomb H.H.; Thaker G.K.; Buchanan R.; Medoff D.R.; Tamminga C.A.

Sensorimotor cortex and supplementary motor area changes in schizophrenia: studies with functional magnetic resonance imaging
pp. 172-172(1)
Authors: Schroder J.; Schad L.R.; Jahn T.; Gerdssen I.; Wenz F.; Linke A.; Baudendistel K.; Knopp M.V.

Functional MRI of attention in relatives of schizophrenic patients
pp. 172-172(1)
Authors: Seidman L.J.; Goldstein J.M.; Breiter H.C.; Goodman J.M.; Ward M.; Woodruff P.; Faraone S.V.; Kennedy D.N.; Weisskoff R.M.; Rosen B.R.; Tsuang M.T.

The effect of an atypical antipsychotic (risperidone) on temporal lobe and prefrontal cortex activity in schizophrenia
pp. 173-173(1)
Authors: Speer A.M.; Risch S.C.; Hammer M.B.; Molloy M.; Ulmer H.G.; De Vane C.L.; Vincent D.J.; George M.S.

A pet study of word generation in obligate carriers of the predisposition to schizophrenia
pp. 173-173(1)
Authors: Spence S.A.; Sharma T.; Hellewell J.; Stefan M.; Grasby P.; Deakin B.; Murray R.; Frith C.; Liddle P.

Altered lateralisation of auditory cortical response to external speech in schizophrenia
pp. 173-173(1)
Authors: Woodruff P.W.R.; Wright I.C.; Brammer M.; Bullmore E.T.; Howard R.; David A.S.; Shapleski J.; Rossell S.; Andrew C.; Williams S.C.R.; Murray R.M.

FMRI of schizophrenics and normal controls during verbal recall
pp. 174-174(1)
Authors: Yurgelun-Todd D.A.; Baird A.A.; Gruber S.A.; Cohen B.M.; Renshaw P.F.

Ketamine induced time effect by principal component analysis
pp. 174-174(1)
Authors: Zhao Z.; Holcomb H.H.; Lahti A.C.; Chen L.-W.; Medoff D.; Tamminga C.A.

SPECT measurement of human striatal synaptic dopamine concentration with [¹²³I]IBZM
pp. 175-175(1)
Authors: Abi-Dargham A.; Kegeles L.; Malaspina D.; Clark S.; Gorman J.; Mann J.; van Heertum R.; Laruelle M.

Multivariate cluster analysis of dynamic [I-123]-IBZM SPET dopamine D2 receptor images in schizophrenia
pp. 175-175(1)
Authors: Acton P.D.; Pilowsky L.S.; Costa D.C.; Ell P.J.

Preliminary assessment of cortical GABA levels in schizophrenics using magnetic resonance spectroscopy
pp. 175-176(2)
Authors: Behar K.; Rothman D.; D'Souza D.C.; Gil R.; Petroff O.; Abi-Saab D.; Zuzarte E.; Hooten M.; Petrakis I.; Sernyak M.; White J.; Webb E.; Charney D.; Krystal J.

Brain DOPA-decarboxylase (DDC) activity in unmedicated schizophrenic patients
pp. 176-176(1)
Authors: Benkelfat C.; Nishizawa S.; Kuwabara H.; Lal S.; Chouinard G.; Cumming P.; Labelle A.; Joober R.; Bruce K.; Diksic M.; Gjedde A.

Assessment of synaptic dopamine concentrations in schizophrenia with PET
pp. 176-176(1)
Authors: Breier A.; Su T.-P.; Saunders R.; Carson R.E.; Kolachana B.S.; Weisenfeld N.; Malhotra A.K.; Elman I.; Eckelman W.C.; Pickar D.

5-HT_2A receptor blockade in vivo in schizophrenic patients treated with atypical antipsychotics: single photon emission tomography (SPET) findings
pp. 176-177(2)
Authors: Busatto G.F.; Travis M.J.; Pilowsky L.S.; Costa D.C.; Mulligan R.; Mertens J.; Terriere D.; Ell P.J.; Acton P.; Gacinovic S.; Okocha C.; Leysen J.E.; Kerwin R.W.

Proton magnetic resonance spectroscopy (¹H MRS) of pons and cerebellum in schizophrenic patients
pp. 177-177(1)
Authors: Eluri R.; Boyko O.B.; Paul C.R.; Roemer R.A.

The maudsley early onset schizophrenia study: brain structural and maturational abnormalities in schizophrenic adolescents
pp. 177-177(1)
Authors: Frangou S.; Simmons A.; Andrews C.; Clover A.; Williams S.; Pipe R.; Murray R.M.

Hemispheric asymmetry of benzodiazepine receptor binding sites in schizophrenia--a study with ¹²³I-iomazenil-SPECT
pp. 177-178(2)
Authors: Gerdsen I.; Pinkert J.; Oehme L.; Ripke B.; Zoephel K.; Neumann U.; Bach O.; Franke W.G.

5HT₂ and D₂ receptor occupancy of ziprasidone in healthy volunteers
pp. 178-178(1)
Authors: Gunn K.P.; Miceli J.J.; Rubin R.H.; Frackowiak R.S.J.; Williams S.A.; Fischman A.

Proton MRS in first episode patients with schizophrenia: abnormalities in NAA and CHO ratios to creatine in frontal and temporal lobes
pp. 178-178(1)
Authors: Gur R.E.; Lenkinski R.; Cesil K.; Gur R.C.

D₁-dopamine receptors in schizophrenia examined by PET
pp. 178-179(2)
Authors: Karlsson P.; Farde L.; Halldin C.; Sedvall G.

Hippocampal proton magnetic resonance spectroscopy (MRS) study in schizophrenia
pp. 179-179(1)
Authors: Kegeles L.S.; Shungu D.C.; Chan S.; Malaspina D.; Mann J.J.; Gorman J.M.; Kaufmann C.A.

In vivo evaluation of dopamine synaptic function in untreated schizophrenic patients
pp. 179-179(1)
Authors: Laruelle M.; Abi-Dargham A.; Krystal J.H.; Charney D.S.; Innis R.B.

Proton spectroscopy reveals normal NAA concentration in cortical gray matter in schizophrenic patients
pp. 179-180(2)
Authors: Lim K.O.; Adalsteinsson E.; Spielman D.; Sullivan E.V.; Pfefferbaum A.

Alteration in Cho/Cre in the left temporal lobe of chronic schizophrenics
pp. 180-180(1)
Authors: Moore C.M.; Bonello C.M.; Sherwood A.R.; Cohen B.M.; Renshaw P.F.; Yurgelun-Todd D.A.

Neuro-receptor imaging in three-dimensions in vivo and in vitro: application to dopamine and benzodiazepine receptors
pp. 180-180(1)
Authors: Pauli S.; Hall H.; Halldin C.; Sedvall G.

A 123I IBZM spet study of striatal D2 receptors in sertindole treated patients
pp. 180-181(2)
Authors: Pilowsky L.S.; O'Connell P.; Davies N.; Busatto G.F.; Costa D.C.; Ell P.J.; Kerwin R.W.

Preliminary report: effects of clozapine and typical antipsychotics on striatal and limbic dopamine D2/D2-like receptors in vivo by 123I epidepride spet
pp. 181-181(1)
Authors: Pilowsky L.S.; Mulligan R.S.; Acton P.D.; Gacinovic S.; Busatto G.F.; Kessler R.M.; Ell P.J.; Travis M.J.; Bigliani V.; Stephenson C.; Costa D.C.; Kerwin R.W.

Striatal D2 receptor binding in olanzapine treated patients estimated by 123I IBZM spet (single photon emission tomography).
pp. 181-181(1)
Authors: Pilowsky L.S.; Busatto G.F.; Taylor M.; Costa D.C.; Sharma T.; Sigmundssen T.; Ell P.J.; Nohria V.; Kerwin R.W.

NAA/Cre ratio correlates with verbal memory
pp. 182-182(1)
Authors: Sherwood A.R.; Gruber S.A.; Moore C.M.; Yurgelun-Todd D.A.

Frontal lobe in vivo proton magnetic resonance spectroscopy in schizophrenic patients with negative symptoms
pp. 182-182(1)
Authors: Sigmundsson T.; Toone B.K.; Maier M.; Williams S.C.R.; Simmons A.; Greenwood K.; Ron M.A.

Medial prefrontal ¹H MRS findings in never-treated schizophrenics and healthy controls
pp. 182-182(1)
Authors: Williamson P.C.; Bartha R.; Drost D.J.; Malla A.; Carr T.J.; Cortese L.; MacFabe G.C.; Rylett R.J.; Neufeld W.R.J.

Multiple lines of evidence for dopamine dysfunction in psychosis by imaging
pp. 183-183(1)
Authors: Wong D.F.; Gjedde A.; Reith J.; Grunder G.; Szymanski S.; Yokoi F.; Hong C.; Nestadt G.; Neufeld K.; Pearlson G.; Tune L.; Angrist B.

A comparison of two atypical antipsychotics in treatment resistant schizoprehnia
pp. 185-185(1)
Authors: Flynn S.W.; MacEwan G.W.; Altman S.; Kopala L.C.; Smith G.N.; Honer W.G.

Pimozide augmentation for the treatment of partial responders to clozapine
pp. 185-185(1)
Authors: Joseph I.; Friedman M.D.; Ault R.N.K.; Powchik M.D.P.

Treatment of clozapine-induced weight gain with phenylpropanolamine
pp. 185-186(2)
Authors: Borovicka M.C.; Fuller M.A.; Konicki P.E.; Brescan D.; Popli A.; Jurjus G.; Kong K.; Steele V.; White J.; Jaskiw G.E.

An open-label assessment of the impact of clozapine on biological, psychosocial and economic variables
pp. 186-186(1)
Authors: Chatterton R.; McGrath J.

Symptom profile and functional ability in treatment-refractory schizophrenia: evidence for a differential impact of clozapine
pp. 186-186(1)
Authors: Chatteron R.; Boschen M.; van Leent S.; McGrath J.

A pharmacoeconomic analysis of clozapine therapy in treatment-refractory schizophrenia
pp. 186-186(1)
Authors: Konicki P.E.; Manuel M.; Kwon K.; Jurjus G.; Jaskiw G.E.

Clozapine treatment in neuroleptic resistant schizophrenia in Barbados
pp. 186-187(2)
Authors: Malesu R.R.; Harding S.

Effectiveness of clozapine in treatment resistant schizophrenia
pp. 187-187(1)
Authors: Marder S.R.; Kane J.M.; Schooler N.R.; Wirshing W.C.; Baker R.; Ames D.; Umbricht D.; Ganguli R.; Borenstein M.

Remediation of neuropsychological impairments with clozapine
pp. 187-187(1)
Authors: Mortimer A.M.; Dye S.

Clinical and brain imaging effects of adjunctive high dose glycine with clozapine in schizophrenia
pp. 187-188(2)
Authors: Potkin S.G.; Yi J.; Bunney B.; Gulasekaram B.; Costa J.; Keator D.B.; Telford J.; Wu J.C.; Najafi A.; Bunney W.E.

Clozapine enhances neurocognition and clinical symptoms more than standard neuroleptics
pp. 188-188(1)
Authors: Potkin S.G.; Fleming K.; Telford J.; Costa J.; Gulasekaram B.; Yi J.

A randomized, double-blind trial of the efficacy and cost-effectiveness of clozapine
pp. 188-188(1)
Authors: VA CSHS17 Study Group; Rosenheck R.; Charney D.; Cramer J.; Weichun X.; Thomas J.

First improvement with clozapine: how patient should we be?
pp. 188-188(1)
Authors: Schooler N.; Borenstein M.; Ames D.; Baker R.; Umbricht D.; Wirshing W.; Kane J.; Marder S.

Effects of clozapine on cognitive functions in treatment-refractory schizophrenia
pp. 188-189(2)
Authors: Stone W.S.; Seidman L.J.; Kalinowski A.; Shagrin B.; Patel J.K.; Shafa R.; Canuso C.; Schildkraut J.J.; Green A.I.

Predictors of response to clozapine in a long-term double blind treatment study
pp. 189-189(1)
Authors: Umbricht D.; Ames D.; Wirshing W.C.; Baker R.; Chengappa R.; Borenstein M.; Schooler N.; Marder S.; Kane J.

Time required for initial improvement during clozapine treatment of refractory schizophrenia
pp. 189-189(1)
Author: Wilson W.H.

Demographic differences in olanzapine responders with therapy-refractory schizophrenia
pp. 189-190(2)
Authors: Conley R.; Gounaris C.

Olanzapine response in therapy-refractory schizophrenia with substance abuse (SA)
pp. 190-190(1)
Authors: Conley R.; Gale E.; Hirsch K.

Olanzapine vs. chlorpromazine in therapy-refractory schizophrenia
pp. 190-190(1)
Authors: Conley R.R.; Tamminga C.A.; Beasley C.

The efficacy of olanzapine treatment in patients previously treated with clozapine
pp. 190-190(1)
Authors: Lingle J.S.; Peszke M.A.; Kent D.; Conley R.

Olanzapine response in schizophrenic subjects with neuroleptic resistant disorganization
pp. 191-191(1)
Authors: Richardson C.; Conley R.

Treatment failure with clozapine: can olanzapine be the alternative therapy?
pp. 191-191(1)
Authors: Tollefson G.D.; Tran P.V.; Birkett M.; Shoshani D.

Olanzapine versus risperidone in the treatment of psychosis. Preliminary report
pp. 191-192(2)
Authors: Tollefson G.D.; Tran P.V.; Hamilton S.; Kuntz A.

The course of primary and secondary negative symptoms in a controlled trial with olanzapine
pp. 192-192(1)
Authors: Tollefson G.D.; Sanger T.M.; Beasley C.M.

Comorbid mood disturbance in schizophrenia
pp. 192-192(1)
Authors: Tollefson G.D.; Lu Y.

Olanzapine in the treatment of schizoaffective disorder
pp. 192-193(2)
Authors: Tollefson G.D.; Lu Y.; Sanger T.M.; Beasley C.M.; Tran P.V.

Olanzapine versus haloperidol in the treatment of first episode psychosis
pp. 193-193(1)
Authors: Tollefson G.D.; Sanger T.M.; Lieberman J.A.

Efficacy of risperidone in first-episode schizophrenia
pp. 193-193(1)
Authors: Ahmed S.; Schooler N.; Montrose D.; Haas G.; Sweeney J.; Keshavan M.S.

Risperidone vs. haloperidol in treatment resistant schizophrenia
pp. 193-194(2)
Authors: Ames D.; Wirshing W.C.; Marshall B.D.; Green M.F.; McGurk S.R.; Mintz J.; Marder S.R.

A six month trial of risperidone versus conventional neuroleptics in young patients with early onset schizophrenia
pp. 194-194(1)
Authors: Ferrari M.C.L.; Elkis H.

Risperidone for first episode schizophrenia: symptom response to lower, intermediate and higher dose strategies
pp. 194-194(1)
Authors: Kopala L.C.; Good K.P.; Fredrikson D.; Whitehorn D.; Lazier L.; Honer W.G.

Risperidone treatment in polydipsia and intermittent hyponatremia
pp. 194-195(2)
Authors: Leadbetter R.A.; Shutty M.S.; Pavalonis D.; Higgins P.

Psychopathological and neuropsychological profile of clozapine vs. risperidone in refractory schizophrenics
pp. 195-195(1)
Authors: Lindenmayer J.-P.; Iskander A.; Park M.; Smith R.; Apergi F.-S.; Czobor P.

Risperidone versus haloperidol in a prospective longitudinal follow-up of recent-onset schizophrenia
pp. 195-195(1)
Authors: Miller D.D.; Ziebell S.; Nopoulos P.; Andreasen N.C.

The use of risperidone in preadolescent children
pp. 195-196(2)
Authors: Nasrallah H.A.; Gehm N.M.; Votolato N.

Pilot study of atypical antipsychotic agents in first episode schizophrenia
pp. 196-196(1)
Authors: Robinson D.G.; Lieberman J.A.; Sheitman B.; Alvir J.M.J.; Kane J.M.

Efficacy, safety and tolerability of 'Seroquel' (quetiapine) in elderly subjects with psychotic disorders
pp. 196-196(1)
Authors: Arvanitis L.A.; Rak I.W.

The long-term efficacy and safety of 'Seroquel' (quetiapine)
pp. 196-197(2)
Authors: Arvanitis L.A.; Rak I.W.

The neurocognitive effects of quetiapine ('Seroquel', ICI 204,636)
pp. 197-197(1)
Authors: Fleming K.; Kalali A.; Chio Y.; Vargo D.L.; Thyrum P.T.; Potkin S.G.

'Seroquel' (quetiapine), a promising new antipsychotic agent: overview of safety and tolerability
pp. 197-197(1)
Authors: Goldstein J.M.; Arvanitis L.A.

'Seroquel' (quetiapine) is not associated with dose-related extrapyramidal symptoms: overview of clinical results
pp. 198-198(1)
Authors: Goldstein J.M.; Arvanitis L.A.

In vitro prediction of potential metabolic drug interactions for Seroquel
pp. 198-198(1)
Authors: Grimm S.W.; Stams K.R.; Bui K.

Patients' satisfaction with and acceptability of Seroquel
pp. 198-199(2)
Authors: Kalali A.H.; Potkin S.G.

Pharmacokinetics and safety of lithium co-administered with 'Seroquel' (quetiapine)
pp. 199-199(1)
Authors: Potkin S.G.; Thyrum P.T.; Bera R.; Vargo D.; Carreon D.; Kalali A.; Maguire G.; Chiao Y.; Ewing B.J.; Wong Y.W.J.

Overview of the efficacy of 'Seroquel' (quetiapine)
pp. 199-199(1)
Authors: Rak I.W.; Arvanitis L.A.

Multiple-dose pharmacokinetics of 'Seroquel' (quetiapine) in elderly psychotic patients
pp. 199-200(2)
Authors: Wong Y.W.J.; Ewing B.J.; Thyrum P.T.; Chiao Y.

Multiple-dose pharmacokinetics of 'Seroquel' (quetiapine) in schizophrenic men and women
pp. 200-200(1)
Authors: Wong Y.W.J.; Ewing B.J.; Thyrum P.T.; Chiao Y.

Pharmacokinetics of 'Seroquel' (quetiapine) in hepatic and renal insufficiency
pp. 200-200(1)
Authors: Wong Y.W.J.; Ewing B.J.; Thyrum P.T.; Chiao Y.

The effect of phenytoin and cimetidine on the pharmacokinetics of Seroquel
pp. 200-201(2)
Authors: Wong Y.W.J.; Ewing B.J.; Thyrum P.T.; Chiao Y.

Sertindole's improvement of negative symptoms, is it independent of extra-pyramidal symptoms, depression and positive symptoms?
pp. 201-201(1)
Authors: Bark N.; Moynihan N.; Da Silva-Siegel D.

The safety and tolerability of sertindole in elderly patients with dementia
pp. 201-201(1)
Authors: Buckley P.; Cutler N.; Silber C.; O'Neil J.; Mack R.

Reduction of hospital days in sertindole treated patients: one year findings
pp. 201-202(2)
Authors: Ereshefsky L.; Nabulsi A.; Silber C.; Mack R.

Population pharmacokinetics of sertindole during long-term treatment of patients with schizophrenia
pp. 202-202(1)
Authors: Granneman R.; Wozniak P.; Tran-Johnson T.; Silber C.; Mack R.

The action of sertindole on negative symptoms in schizophrenia
pp. 202-202(1)
Authors: Lahti A.; Silber C.; Mack R.

The long term cardiovascular safety of sertindole
pp. 202-202(1)
Authors: Ramirez L.; Silber C.; Mack R.

The atypical antipsychotic sertindole: a case series
pp. 203-203(1)
Authors: Suppes T.; Lee A.; Paul B.; Sanchez B.; Mack R.

A multi-center, one year, haloperidol controlled trial assessing the long term safety, efficacy and quality of life of sertindole in stable schizophrenic patients
pp. 203-203(1)
Authors: Swann A.; Holgate K.; Staser J.; Silber C.; Mack R.

Comparing sertindole clinical data and patients across the oceans
pp. 203-203(1)
Authors: Wehnert A.; van der Burght M.; Sloth-Nielsen M.

The efficacy and safety of ziprasidone 80 mg/day and 160 mg/day in schizophrenia and schizoaffective disorder
pp. 204-204(1)
Authors: Daniel D.; Reeves K.; Harrigan E.P.

New psychotropic drugs for schizophrenia: recently arrived, in development and never arrived
pp. 204-204(1)
Authors: Glick I.D.; Belanoff J.K.

A rapid tranquillization protocol
pp. 204-204(1)
Authors: Ainsworth C.; Catts S.V.

Obstetric complications predict treatment response in first episode schizophrenia
pp. 204-205(2)
Authors: Alvir J.M.J.; Woerner M.G.; Gunduz H.; Lieberman J.A.

Compliance with maintenance medication in first-episode schizophrenia
pp. 205-205(1)
Authors: Barnes T.R.E.; McPhillips M.A.; Hillier R.; Puri B.K.; Joyce E.

Satisfaction with treatment outcome and noncompliance in schizophrenia
pp. 205-205(1)
Authors: Blyler C.R.; Fenton W.S.

Methylphenidate treatment of negative symptoms in schizophrenia
pp. 205-206(2)
Authors: Brescan D.W.; Jaskiw G.E.; Konicki P.E.

Evaluating ability to consent in psychotic inpatients
pp. 206-206(1)
Authors: Conley R.R.; Zaremba S.; McMullen R.; Love R.

Quantitative measurement of antipsychotic medication compliance in chronic schizophrenic patients
pp. 206-206(1)
Authors: Diaz E.; Levine H.B.; Sullivan M.C.; Sernyak M.J.; Hawkins K.A.; Cramer J.A.; Woods S.W.

Dose reduction in patients with schizophrenia receiving very high doses of typical antipsychotic drugs
pp. 206-207(2)
Authors: Fuller M.A.; Konicki P.E.; Borovicka M.C.; Jurjus G.; Popli A.; Brescan D.; Kwon K.Y.; Jaskiw G.E.

Selection bias in clinical trials with antipsychotics
pp. 207-207(1)
Authors: Hummer M.; Kurz M.; Kohl C.; Walch T.; Fleischhacker W.W.

The treatment of schizophrenia with partial dopamine agonist: a promising strategy
pp. 207-207(1)
Authors: Lahti A.C.; Lahti R.A.; Carlsson A.; Tamminga C.A.

Unexplored issues in schizophrenia clinical trials implementation
pp. 207-207(1)
Author: Mason S.E.

The effect of nifedipine on akathisia and agitation in patients with movement disorders
pp. 208-208(1)
Authors: McCarthy M.F.; Kendrick K.A.; Rosse R.B.; Schwartz B.L.; Peace T.; Wyatt R.J.; Deutsch S.I.

Is early intervention effective and cost effective?
pp. 208-208(1)
Authors: McGorry P.D.; Edwards J.; Mihalopoulos C.; Jackson H.

Very low dose neuroleptic-treatment of first episode psychosis--is it feasible in routine clinical care?
pp. 208-208(1)
Authors: McGorry P.D.; Cocks J.; Longley T.; Webster K.; Elkins K.; Hallgren M.; Plowright D.

The use of sodium valproate to treat post-psychotic depression
pp. 208-209(2)
Authors: Mikhnyak S.I.; Vlokh I.Y.

Fatty acid supplementation in schizophrenic patients
pp. 209-209(1)
Authors: Peet M.; Laugharne J.D.E.; Ahluwalia N.; Mellor J.

A preliminary study of the safety and efficacy of guanfacine for the treatment of cognitive and negative symptoms in schizophrenia
pp. 209-209(1)
Authors: Powchik P.; Friedman J.; Remenson L.; Smith M.

Glycine transport inhibitors: A new class of antipsychotics?
pp. 211-211(1)
Authors: Borden L.A.; Bell S.C.; Ognyanov V.I.; Albert V.R.; Zhang J.; De Vivo M.; Yokoyama M.; Xie X.; Berger T.; Gerhardt G.; McKelvy J.F.

CNS catecholamines and cognitive dysfunction in schizophrenia
pp. 211-211(1)
Authors: Carter C.S.; Barch D.; Cohen J.D.; Braver T.

Persistent behavioral changes and progressive sensitization in amphetamine sensitized rhesus monkeys
pp. 211-211(1)
Authors: Castner S.A.; Goldman-Rakic P.S.

Antisaccade, clinical and motor executive functions in schizophrenia: effects of 5HT2 antagonist; cyproheptadine
pp. 212-212(1)
Authors: Chaudhry I.B.; Soni S.D.; Hellewell J.S.E.; Deakin J.F.W.

Systematic comparison of the behavioural profiles of three new D₃ dopamine receptor antagonists
pp. 212-212(1)
Authors: Clifford J.; Waddington J.L.

Attention, clinical symptoms and pharmacology in schizophrenia
pp. 212-213(2)
Authors: Cornblatt B.; Obuchowski M.; Andreasen A.

Glycine ketamine interactions in healthy humans
pp. 213-213(1)
Authors: D'Souza D.C.; Gil R.; Zuzarte E.; Abi-Saab D.; Damon D.; White J.; Zimmerman L.; Krystal J.

Tetrahydrocannabinol effects in schizophrenic subjects & healthy controls
pp. 213-213(1)
Authors: D'Souza D.C.; Gil R.; Zuzarte E.; Zimmerman L.; Abi-Saab D.; Damon D.; White J.; Sernyak M.; Krystal J.

Sensitization with clozapine increases focal CNS excitability can this effect be useful clinically?
pp. 213-214(2)
Authors: Denney D.D.; Stevens J.R.; Szot P.

The effects of clozapine on plasma norepinephrine kinetics in schizophrenic patients
pp. 214-214(1)
Authors: Elman I.; Goldstein D.S.; Holmes C.; Adler C.; Pickar D.; Breier A.

Risperidone's effects on verbal working memory
pp. 214-214(1)
Authors: Green M.F.; Marshall B.D.; Wirshing W.C.; Ames D.; Marder S.R.; McGurk S.; Kern R.S.; Mintz J.

Clozapine: elevation of membrane unsaturated lipid levels as a new mechanism of action
pp. 214-214(1)
Authors: Horrobin D.F.; Glen A.I.M.; Cantrill R.C.

Risperidone vs. haloperidol on reaction time and fine motor speed
pp. 215-215(1)
Authors: Kern R.S.; Green M.F.; Marshall B.D.; Wirshing W.C.; Ames D.; Marder S.R.; McGurk S.; Mintz J.

The NMDA receptor and schizophrenia: from phenotype to genotype
pp. 215-215(1)
Authors: Malhotra A.K.; Breier A.; Buchanan R.; Goldman D.; Pickar D.

Adjunctive loxapine in a clozapine-resistant cohort of sdhizophrenic patients
pp. 215-215(1)
Authors: Mowerman S.; Siris S.G.

Dose-dependent insulin-induced increases in memory performance in healthy humans
pp. 215-216(2)
Authors: Newcomer J.W.; Coleman J.; Bhargava N.; Selke G.; Kelly A.; White D.

Response to amphetamine challenge and the three dimension hypothesis of schizophrenia
pp. 216-216(1)
Authors: Pandurangi A.K.; Thacker L.

Predicting clozapine response: systematic evaluation of allelic variation in candidate genes
pp. 216-216(1)
Authors: Pickar D.; Goldman D.; Buchanan R.; Breier A.; Malhotra A.K.

Valproate and force control during clozapine treatment in schizophrenic patients
pp. 216-216(1)
Authors: Popli A.P.; Jaskiw G.E.; Vrtunski P.B.

Assessment and interpretation of noncompliance with oral haloperidol
pp. 217-217(1)
Authors: Radomsky E.D.; Perel J.M.; Gurklis J.A.; van Kammen D.P.

Cognitive dysfunction and its treatment in schizotypal personality disorder
pp. 217-217(1)
Author: Siever L.J.

The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers
pp. 217-218(2)
Authors: Van Berckel B.N.M.; Lipsch C.; Gispen-de Wied C.; Wynne H.J.; Blankenstein R.A.; van Ree J.M.; Kahn R.S.

Dose-related ethanol effects in schizophrenic patients
pp. 218-218(1)
Authors: Zuzarte E.; D'Souza D.C.; Gil R.; Genovese A.; White J.; Charney D.S.; Krystal J.H.

Evaluation of lorazepam blockade of m-chlorophenylpiperazine (MCPP) effects in schizophrenia
pp. 218-218(1)
Authors: Zuzarte E.; D'Souza D.C.; Gil R.; White J.; AbiSaab D.; Charney D.S.; Krystal J.H.

A questionnaire to assess the burden of the family in chronic schizophrenia: comparison with families of mood disorders patients
pp. 219-219(1)
Authors: Abdo C.H.N.; Elkis H.

Cognitive behavioral treatment of panic attacks in chronic schizophrenia
pp. 219-219(1)
Authors: Arlow P.B.; Moran M.E.; Bermanzohn P.C.; Siris S.G.

Cognitive impairment and work behavior in schizophrenia
pp. 219-219(1)
Authors: Bell M.; Kaplan E.A.; Bryson G.

Quality of life in first episode schizophrenia/schizophreniform disorder
pp. 219-220(2)
Authors: Browne S.; Gervin M.; Lane A.; Morris M.; Larkin C.; Waddington J.L.; O'Callaghan E.

The work behavior inventory: a scale for the assessment of work behavior for clients with severe mental illness
pp. 220-220(1)
Authors: Bryson G.; Bell M.; Lysaker P.; Zito W.

The port pharmacological treatment recommendations
pp. 220-220(1)
Authors: Buchanan R.W.; Zito J.; Lyles A.; Lehman A.F.

PQCSPI, an instrument to measure the perception of quality of care for psychotic inpatients
pp. 220-220(1)
Authors: De Hert M.; Abrahams F.; Van Bouwel L.; Peuskens J.

Informal caregivers and schizophrenia: a pilot study
pp. 221-221(1)
Authors: Dharwadkar N.; Kulkarni J.

Adherence to schizophrenia port family treatment recommendations
pp. 221-221(1)
Authors: Dixon L.; Scott J.; Lyles A.; Fahey M.; Skinner A.; Shore A.

Quality of subjective life experience in schizophrenia-spectrum disorders
pp. 221-221(1)
Authors: Dott S.G.; Walling D.P.

Predicting rehabilitation outcome in schizophrenia
pp. 221-222(2)
Authors: Ferdinandi A.; Pollack S.; Bermanzohn P.C.

Successful vocational functioning in schizophrenia
pp. 222-222(1)
Authors: Gold J.M.; Bryant N.L.; Vladar K.; Buchanan R.W.

Disseminating treatment recommendations from the schizophrenia P.O.R.T.
pp. 222-222(1)
Authors: Goldman H.H.; McGlynn E.A.

Quality of life in schizophrenia: affiliative and instrumental domains
pp. 222-222(1)
Authors: Goodman M.S.; Hull J.W.; Terkelsen K.G.; Smith T.E.

Quality of life in schizophrenia: symptom, insight and neuropsychological determinants
pp. 223-223(1)
Authors: Goodman M.S.; Smith T.E.; Hull J.W.; Felger T.E.; Hedayat-Harris A.; Walsh C.A.; Raymond S.C.; Weiss K.A.

Intensive cognitive-behavioural therapy for recent onset schizophrenia: a pilot study
pp. 223-223(1)
Authors: Haddock G.; Hopkins R.; Tarrier N.; Morrison T.; Lewis S.

The dependence on financial support from social agencies early in the course of schizophrenia
pp. 223-223(1)
Authors: Ho B.-C.; Flaum M.; Andreasen N.

Determining the true costs of bed-and-board for the seriously mentally ill. I. psychiatric hospitals
pp. 223-224(2)
Author: Honigfeld G.

Successful transition from the hospital to the community
pp. 224-224(1)
Authors: Kopelowicz A.; Zarate R.; Wallace C.J.

Identifying dynamical patterns in vocational rehabilitation of schizophrenic patients
pp. 224-224(1)
Authors: Kupper Z.; Hoffmann H.

Psychosocial rehabilitation in first-episode psychosis (FEP): experience with an FEP group
pp. 224-225(2)
Authors: Lazier L.; LeBlanc A.; Whitehorn D.; Kopala L.

Translating research into practice: disease management for schizophrenia
pp. 225-225(1)
Author: Lehman A.F.

Untreated psychosis and early intervention in recent onset schizophrenia
pp. 225-225(1)
Authors: Linszen D.H.; Lenior M.E.; Dingemans P.M.

Extroversion and work performance in schizophrenia
pp. 225-225(1)
Authors: Lysaker P.; Bell M.; Bryson G.

A group program for recovery from early psychosis
pp. 225-226(2)
Authors: Albiston D.J.; Francey S.M.; Harrigan S.M.; McGorry P.D.

Cognitively-oriented psychotherapy for early psychosis (COPE): preliminary results
pp. 226-226(1)
Authors: McGorry P.D.; Jackson H.; Edwards J.; Hulbert C.; Henry L.; Francey S.; Maude D.; Cocks J.; Power P.; Harrigan S.; Dudgeon P.

Patients subjective illness concepts about chronic schizophrenia--a comparison of views seen by patients and psychiatrists in office practice of East Germany after reunification
pp. 226-227(2)
Authors: Ripke B.; Schellong J.; Triemer A.; Glasner F.; Bach O.

Comparing general social skills training with specific cognitive behaviour therapy: results of a multi-center study
pp. 227-227(1)
Authors: Roder V.; Muller D.; Brenner H.D.

Coping strategies in relatives of patients with schizophrenia
pp. 227-227(1)
Authors: Scazufca M.; Kuipers E.

Quality of life and its relationship to patterns of service use among individuals with schizophrenia
pp. 227-227(1)
Authors: Scott J.E.; Lehman A.F.; Dixon L.B.; Postrado L.; Lyles A.; Skinner A.; Fahey M.

Cost study of intensive psychiatric community care for patients with psychosis
pp. 228-228(1)
Authors: Semple W.E.; Steiner E.; McCormick R.; Vernon L.; Schulz S.C.; Goyer P.F.

Acquisition of treatment compliance skills during recovery from acute exacerbation in schizophrenia
pp. 228-228(1)
Authors: Smith T.E.; Hull J.W.; Romanelli S.J.; Hedayat-Harris A.; Corriss D.J.; Goodman M.S.; Anthony D.T.

Factors associated with social behavior deficits in recently discharged schizophrenic patients
pp. 228-228(1)
Authors: Smith T.E.; Hull J.W.; Hedayat-Harris A.; Romanelli S.J.; Weiss K.A.; Raymond S.C.

Early detection and intervention programs for psychosis: service module development
pp. 228-229(2)
Authors: Spencer E.A.; O'Donnell M.C.; Shaw J.; Stewart K.; Still M.; Catts S.V.

Do mentally ill patients perceive their family members' expressed emotion?
pp. 229-229(1)
Authors: Tompson M.C.; Goldstein M.J.; Weisman A.

Cognitive adaptation training: the use of compensatory strategies for inpatients and outpatients with schizophrenia
pp. 229-229(1)
Authors: Velligan D.I.; Mahurin R.K.; Eckert S.L.; Miller A.L.; Bow-Thomas C.C.

First-episode schizophrenia: parent's role in determining the duration of untreated psychosis
pp. 230-230(1)
Authors: Whitehorn D.; Bayer M.J.; Kopala L.

P50 auditory gating, ffts, and plasma metabolites in schizophrenia
pp. 231-231(1)
Authors: Adler L.E.; McRae K.A.; Cawthra E.; Ascarrunz F.; Gerhardt G.; Huettl P.; Levin D.; Abrams R.; Freedman R.

Schizophrenic patients with normal prepulse inhibition?
pp. 231-231(1)
Authors: Perry W.; Geyer M.; Cadenhead K.; Swerdlow N.; Braff D.

Brain event-related potentials in schizophrenia during a visuospatial task
pp. 231-232(2)
Authors: Bruder G.; Kayser J.; Tenke C.; Friedman M.; Rabinowicz E.; Amador X.; Gorman J.

P50 suppression deficits among the relatives of schizophrenia patients
pp. 232-232(1)
Authors: Clementz B.A.; Geyer M.A.; Braff D.L.

Effects of haloperidol on the event-related potential in schizophrenics
pp. 232-232(1)
Authors: Condray R.; Steinhauer S.R.; Cohen J.D.; van Kammen D.P.; Kasparek A.; Kelley M.E.

Electrophysiology of differential cognitive load: an EEG study examining the frontal cortex
pp. 232-233(2)
Authors: Fleming K.; Mosko O.A.; Vovan B.; Chen E.; Yi J.; Potkin S.G.

Automatic but not strategic processing is abnormal in schizophrenics
pp. 233-233(1)
Authors: Ford J.M.; Roth W.T.; Bell C.M.; Yafeng L.; Jain S.; Menon V.; Lim K.O.; Pfefferbaum A.

P50 and experience of hypersensitivity to external stimuli
pp. 233-233(1)
Authors: Yi J.; Bunney W.E.; Hetrick W.P.; Sandman C.; Pateron J.; Potkin S.G.

Single dose challenge predicts clinical response to clozapine: a pharmaco-EEG study
pp. 233-233(1)
Authors: Yi J.; Potkin S.G.; Sandman C.; Bunney W.E.

Absence of cholinergic neurons does not affect brain surface or hippocampal auditory gating in un-anesthetized rats
pp. 233-234(2)
Authors: Johnson R.G.; King A.R.; Wiley R.G.; Rose G.M.

Sensory gating deficit in schizophrenia: relation to cathecholamine metabolites
pp. 234-234(1)
Authors: Kang D.-Y.; Poole J.; McCallin K.; Fein G.; Vinogradov S.

Dissociation of ERP topographies for verbal and nonverbal auditory oddball tasks: findings for schizophrenic patients and healthy controls
pp. 234-234(1)
Authors: Kayser J.; Bruder G.; Tenke C.; Watson J.; Malaspina D.; Amador X.; Gorman J.

Automated analysis of EEG sleep deficits in schizophrenia
pp. 234-235(2)
Authors: Keshavan M.S.; Montrose D.; Miewald J.; Reynolds C.F.

Interactions between the amygdala and prefrontal cortical inputs to nucleus accumbens neurons and their modulation by dopamine receptor activation
pp. 235-235(1)
Authors: Moore H.; Grace A.A.

Improved P50 auditory gating in schizophrenia with clozapine
pp. 235-235(1)
Authors: Nagamoto H.T.; Adler L.E.; Huettl P.; Gerhardt G.; Hea R.; Cawthra E.; Griffith J.; Freedman R.

Event-related potential and cognitive evidence for similar language impairments in schizophrenia and schizotypal personality disorder
pp. 235-236(2)
Authors: Niznikiewicz M.; Voglmaier M.; Seidman L.; Shenton M.; Dickey C.; Rhoads R.; Teh E.; McCarley R.W.

EEG coherence and symptom dimensions in schizophrenia
pp. 236-236(1)
Authors: Norman R.M.G.; Malla A.K.; Williamson P.C.; Morrison-Stewart S.; Helmes E.

The emotional experience of anhedonia: psychophysiology, facial expression, and self report
pp. 236-236(1)
Authors: Putnam K.M.; Neale J.M.

Determinants of the postimperative negative variation in schizophrenic patients and healthy controls
pp. 236-237(2)
Authors: Rockstroh B.; Cohen R.; Klein C.

Temporal P300 asymmetry in first episode schizophrenia
pp. 237-237(1)
Authors: Salisbury D.F.; Sherwood A.R.; Shenton M.E.; Fischer I.A.; Yurgelun-Todd D.A.; Tohen M.; McCarley R.W.

Temporal P300 asymmetry in schizophrenia vs. manic psychosis and controls
pp. 237-237(1)
Authors: Salisbury D.F.; Fischer I.A.; Shenton M.E.; Sherwood A.R.; Mazzoni P.; McCarley R.W.

Encoding vs trace decay: specifying the mechanism underlying auditory working memory dysfunction in schizophrenia
pp. 238-238(1)
Authors: Shelley A.-M.; Javitt D.C.; Vaughan H.G.; Silipo G.

P50 in deficit and nondeficit schizophrenia
pp. 238-238(1)
Authors: Summerfelt A.T.; Kohl K.; Kirkpatrick B.; Buchanan R.W.

Olfactory dysfunction in schizophrenia: relationship to ERP abnormalities
pp. 238-238(1)
Authors: Turetsky B.I.; Moberg P.J.; Doty R.L.; Gur R.C.; Gur R.E.

Auditory event-related potentials (ERP) in first episode and chronic schizophrenia
pp. 238-239(2)
Authors: Umbricht D.; Javitt D.; Bates J.; Pollak S.; Lieberman J.; Kane J.

Event-related potentials (ERP) during a visual working memory task in first episode and chronic schizophrenia
pp. 239-239(1)
Authors: Umbricht D.; Javitt D.; Bates J.; Pollak S.; Lieberman J.; Kane J.

Sensory gating and clinical symptoms in schizophrenia: gender differences
pp. 239-239(1)
Authors: Vinogradov S.; Gourlay M.; Poole J.H.; McCallin K.; Fein G.

N400, indirect semantic priming and formal thought disorder
pp. 240-240(1)
Authors: Weisbrod M.; Kiefer M.; Brunnmaier A.; Spitzer M.

Motion perception deficits in schizophrenic patients and their correlation with abnormal smooth pursuit
pp. 241-241(1)
Authors: Yue C.; Nakayama K.; Holzman P.S.; Levy D.L.; Matthysse S.

Correlates of nailfold plexus visibility in first-episode and chronic schizophrenia
pp. 241-241(1)
Authors: Curtis C.E.; Iacono W.G.; Beiser M.

Eyelid conditioning--a non motivation-dependent tool to investigate temporal lobe function in schizophrenia
pp. 241-242(2)
Authors: Dantendorfer K.; Maierhofer D.; Serim M.; Eberstaller M.

Dynamic eye movements in schizophrenia, affective and schizoaffective disorders--a laboratory investigation using electrooculography
pp. 242-242(1)
Authors: Gerdsen I.; Pinkert J.; Foetzsch R.; Ripke B.; Oeser S.; Oehme L.; Bach O.; Franke W.G.

Neuropsychological correlates of schizophrenics' eye tracking dysfunction: evidence for individual differences
pp. 242-242(1)
Authors: Gooding D.C.; Iacono W.G.; Grove W.M.

Ocular motor performance in schizophrenic patients and neurological patients
pp. 242-243(2)
Authors: Gooding D.C.; Iacono W.G.; Grove W.M.

Smooth pursuit abnormalities in first episode schizophrenic patients
pp. 243-243(1)
Authors: Hutton S.B.; Crawford T.J.; Puri B.K.; Duncan L.-J.; Kennard C.; Barnes T.R.E.; Joyce E.M.

Fast reaction time predictive saccades among schizophrenia patients may be consistent with a failure of inhibition
pp. 243-243(1)
Authors: McDowell J.E.; Blumenfeld L.D.; Clementz B.A.

Attentional measures and eye tracking in the finnish adoptive study of schizophrenia
pp. 243-244(2)
Authors: Moring J.; Wynne L.C.; Asarnow R.; Nuechterlein K.; Holzman P.S.; Hakko H.; Tienari P.

Eye-movement, attentional and frontal dysfunctions in schizophrenia
pp. 244-244(1)
Authors: Obuchowski M.; Cornblatt B.; Tak C.C.; Sweeney J.A.

Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome
pp. 244-244(1)
Authors: Ross D.E.; Thaker G.K.; Buchanan R.W.; Kirkpatrick B.; Lahti A.C.; Medoff D.R.; Bartko J.J.; Goodman J.; Tien A.Y.

Smooth pursuit eye movements in parents of schizophrenic probands; a most likely carrier approach
pp. 244-245(2)
Authors: Ross R.G.; Harris J.; Olincy A.; Radant A.; Adler L.; Freedman R.

Psychostimulant-associated pupillometric detection of subjects endorsing cocaine-induced paranoia
pp. 245-245(1)
Authors: Rosse R.B.; Johri S.K.; Alim T.N.; Ottaviani R.; Deutsch S.I.

A specific deficit in memory guided smooth pursuit eye movements (SPEM) in schizotypal relatives of schizophrenic patients
pp. 245-245(1)
Authors: Thaker G.K.; Ross D.; Kunkel R.; Adami H.

Smooth pursuit eye movements (SPEM) to extraretinal motion signals in schizophrenia
pp. 245-245(1)
Authors: Thaker G.K.; Ross D.; Adami H.; Buchanan R.; Lahti A.

Effects of ketamine on eye tracking in schizophrenia and controls
pp. 246-246(1)
Authors: Weiler M.A.; Thaker G.K.; Lahti A.C.; Ross D.E.; Tamminga C.A.

Prediction of violence in schizophrenic inpatients
pp. 247-247(1)
Authors: Arango C.; Gonzalez T.; Calcedo A.

Psychosis after prenatal exposure to rubella
pp. 247-247(1)
Authors: Brown A.S.; Susser E.; Cohen P.

Neurological soft signs in first episode schizophrenia/schizophreniform psychosis
pp. 247-247(1)
Authors: Browne S.; Gervin M.; Lane A.; Morris M.; Larkin C.; Waddington J.L.; O'Callaghan E.

School performance and later schizophrenia in a finnish birth cohort
pp. 247-248(2)
Authors: Cannon M.; Jones P.; Huttunen M.; Murray R.

A prospective cohort study of genetic and perinatal influences in schizophrenia
pp. 248-248(1)
Authors: Cannon T.D.; Hollister J.M.; Bearden C.E.; Hadley T.

Gender and age-at-onset in the functional psychoses
pp. 248-248(1)
Authors: Castle D.J.; Wessely S.; Murray R.M.

Schizophrenia with onset at the extremes of adult life
pp. 248-249(2)
Authors: Castle D.J.; Wessely S.; Howard R.; Murray R.M.

Intensive use of cocaine in patients with schizophrenia: demographic and other features
pp. 249-249(1)
Authors: Cho J.; Jaskiw G.E.; Strauss M.E.; Goyer P.; Konicki P.E.

Psychiatric morbidity, social development and cognition, and later schizophrenia: premorbid adjustment or prodrome?
pp. 249-249(1)
Authors: David A.S.; Malmberg A.; Lewis G.; Allebeck P.

High prevalence of helicobacter pylori in schizophrenic patients
pp. 249-249(1)
Authors: De Hert M.; De Wilde D.; Reemans J.; Hautekeete M.; Peuskens J.

Homicide in Barbados: a review
pp. 250-250(1)
Authors: Evans C.; Malesu R.R.

Individual patient data meta-analysis of the association between schizophrenia and abnormalities of pregnancy and labour
pp. 250-250(1)
Authors: Geddes J.R.; Verdoux H.; Takei N.; Lawrie S.M.; Murray R.M.

No evidence for more auto-immune pathology in first degree relatives of schizophrenic patients
pp. 250-250(1)
Authors: Guiot S.; De Hert M.; Peuskens J.

Obstetric complications in schizophrenia, affective disorder and normal controls
pp. 251-251(1)
Authors: Gunduz H.; Woerner M.G.; Alvir J.M.J.; Lieberman J.A.

Validity, reliability and relationship to service use and cost of the HoNOS outcome measure scale in adult psychiatric and psychogeriatric services
pp. 251-251(1)
Authors: Hope J.D.; Keks N.A.; Trauer T.